¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2019/8/21 ¤U¤È 02:42:09
²Ä 1283 ½g¦^À³
|
¸¤H¤j¡G ³o´X¤Ñ¬Ý°_¨ÓÀ³¸Ó¬O¤jªÑªF·QÅý¯S©w¤H¤h¤JªÑªº·Pı¡A¤£µMªº¸Ü¤£¥i¯àÀ£§CªÑ»ù¡A¦]¬°¤µ¤Ñ³Ì§C10.85¡Aµ¥©ó¬O·íªì¤jªÑªFªº¦¨¥»»ù10¤¸¡A¥H¤U¬O¥»¤H±À¤å¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/21 ¤U¤È 01:38:01
²Ä 1282 ½g¦^À³
|
³Ì«á¦¬¥½L¡A½L¤¤ÁÙ¦³Â½¬õ¹L¡A¤£ª¾¹D²Ä¤@½L¬Oþ¤@Ó¤j¤á¶Rªº©O? ±ßÂI¦A¨Ó¬Ý¤@¤UÄw½X¡AÄ~Äò¥[ªo¤F! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GªÅÄ_10148533 |
µoªí®É¶¡:2019/8/21 ¤W¤È 09:44:09
²Ä 1281 ½g¦^À³
|
¦Ü¤ÖÅý·Q¨«ªº¥i¥H¨«
¦º½Þ¤£©Èºu¤ô¿S §Ú¨ÌµM¤£Â÷¤£±ó
ÁöµMÁÙ¦³¤@¬q¸ôn¨« ¥[ªo¤F ·PÁ ¦U¦ì«e½ú¥ý¶iªº¤£§[¤À¨É ·P®¦
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G§ë¸ê¬ö«ß10145266 |
µoªí®É¶¡:2019/8/21 ¤W¤È 09:13:15
²Ä 1280 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯Ë¢¦w10144680 |
µoªí®É¶¡:2019/8/21 ¤W¤È 09:11:50
²Ä 1279 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/21 ¤W¤È 09:06:20
²Ä 1278 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/8/21 ¤W¤È 09:03:13
²Ä 1277 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/8/21 ¤W¤È 04:25:17
²Ä 1276 ½g¦^À³
|
¨È·à±dªº¹ï·Ó²Õ¬O³æÃÄ¡AORR³q±`·|¤ñÂù¤ÆÀø§C¤£¤Ö¡C ·|û¡G¤Ñ©R10141925 µoªí®É¶¡:2019/7/31 ¤U¤È 02:03:40²Ä 1147 ½g¦^À³ ¥xÁÞ¤j ¼ÒÀÀ5²Õ ORR¹LÃö,P<5%¤§ª¬ªp ,
(1)°²³] ORR , ¹ï·Ó²Õ 4¤H(4/63=6.3%)¡A¹êÅç²Õ14¤H (14/64=21.9%) (2)°²³] ORR , ¹ï·Ó²Õ 3¤H(3/63=4.8%)¡A¹êÅç²Õ12¤H (12/64=18.8%) (3)°²³] ORR , ¹ï·Ó²Õ 2¤H(2/63=3.2%)¡A¹êÅç²Õ10¤H (10/64=15.6%) (4)°²³] ORR , ¹ï·Ó²Õ 1¤H(1/63=1.6%)¡A¹êÅç²Õ8¤H (8/64=12.5%) (5)°²³] ORR , ¹ï·Ó²Õ 0¤H(0/63=0%)¡A¹êÅç²Õ6¤H (6/64=9.4%)
¦]¹ï·Ó²Õ³æ¤ÆÀø ORR <=1.6%ªº¾÷²v«D±`°ª.(¬Ý¹L¼ÆӨƫá¤ÀªRӮסA¦bµL§Ü·½¿zÀˤU,ORR ¬Û¹ï§C)
ORR ,¥þ³¡(127¤H)Y¦³9¤H ,¸Ñª¼¦¨¥\²v¬Û·í°ª.
µù: )¹ï·Ó²Õ<5¤H¡A¥H¥d¤è¤À°t¥|¤è®æ¤§®Õ¥¿¤½¦¡pºâ.¤@ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/20 ¤U¤È 11:53:41
²Ä 1275 ½g¦^À³
|
¤G½uÁx¹DÀùCape+CisÁp¦X¤ÆÀøÀø®Ä www.ncbi.nlm.nih.gov/m/pubmed/28848173/ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/8/20 ¤U¤È 11:24:36
²Ä 1274 ½g¦^À³
|
¥xÁÞ¤j,
n¬Ý§Ü·½HER®a±Ú¦û¹êÅç²Õªº¤ñ²v¤ÎIHC+2/+3ªº¤ñ²v.
Ó¤H²q ¨È·à±d¦b«÷ORR ¾÷·|°ª, ¥unORR PR , 6 ¤H, PFS/OS ªø¤@ÂI.
---------- ¦pIncyte ¤G½uÁx¹DÀù ¦³FGFR2 §Ü·½47¤H,ORR°ª¹F40%. Interim Results of fight-202, A Phase 2, Open-Label, Multicenter Study of INCB054828 in Patients With Previously Treated Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma (CCA) With/Without Fibroblast Growth Factor (FGF)/FGF Receptor (FGFR) Genetic Alterations
Median PFS was 9.2 months in cohort A (Figure 5) ¡V¡V Median PFS in cohorts B and C were 2.1 and 1.7 months, respectively ¡´¡´ Median OS was 15.8 months in cohort A ¡V¡V Median OS in cohorts B and C were 6.8 and 4.0 months, respectively Figure 5. Kaplan-Meier Estimates of PFS (Assessed by Independent Reviewer)
ESMO 2018: Incyte Posters ---October 22, 2018
investor.incyte.com/events-and-presentations/presentations?field_nir_tags_target_id=All&promote=All&field_nir_asset_type_target_id%5B26%5D=26&items_per_page=10&page=1
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/20 ¤U¤È 11:03:58
²Ä 1273 ½g¦^À³
|
¤Ñ©R¤j ¨È·à±d¤G½uÁx¹DÀùÀø®Ä¦³¥i¯à¶W¹L¥Ø«e¤@½uÁx¹DÀùÀø®Ä ?
¥Ø«e¤@½uÁx¹DÀùÀø®Ä Cisplatin plus Gemcitabine PK Gem
Median PFS 8.0 mo / 5.0 mo
Median overall survival (OS) 11.7 mo / 8.1 mo
2019 ASCO¤j·|³ø§i¤FPD-1 ¤G½uÁx¹DÀù¬ã¨s ( µ²ªG¤]¬O¥O¤H¥¢±æ ) KEYNOTE-158( Á{§É¤G´Á)¬ã¨sªºµ²ªGÅã¥Ü¡AORR¬°5.8%¡]6/104)¡A¤¤¦ì¼Æ OS 7.4Ó¤ë ©M ¤¤¦ì¼Æ PFS 2 Ó¤ë
«Ü¦h¿³ÂdªÑ²¼n¤WÂd¨D¤§¤£¥i±o,¦]¬°Âd¶R¤¤¤ß¹ï¤WÂdn¨D°ª, ¥u¦n¤U¿³Âd¥h§O°êµo®iÄw¸ê, ¨È·à±d¬O²Ä¤@®a¦b¬ü°ê»P¥xÆWÂù±¾µPªº¥xÆW¥Í§Þ¤½¥q¡A¤]¬O²Ä¤@®a¦b¬ü°ê±¾µPªº·s¥[©Y¥Í§Þ¤½¥q,¨È·à±d¦n¤£®e©ö¦b¥x¤WÂd,·|§Q¥Î¥xÆW·s¥[©Y¬°¬ãµo°ò¦a³s±µ¤¤°ê»P¼Ú¬ü¤éÁú, Ó¤H»{¬°°£«D³Q¼Ú¬ü¤jªº¥Í§Þ¤½¥q¨ÖÁʤ~¦³Â÷¶}¥xÆWªº¥i¯à
¥H¤W¬OÓ¤H¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/8/20 ¤U¤È 09:59:52
²Ä 1272 ½g¦^À³
|
¤§«e¼ÒÀÀORR ¹ï·Ó组0¤HPR ¹êÅç组6¤HPR ³o¼Ë´N·|¹LÃö¡C
»¡¹ê¦bORR¹LÃöªº¾÷·|°ª¡C6¤HPR´N¦³¾÷·|¹LÃö¡A¨ä¦s¬¡¦pIycyteªº¤G´Á¡A·|¶W¹L15Ó¤ë¡APFS¶W¹L9Ó¤ë PFSÅܼƤñ¸û¤j¡AYHER®a±Ú§Ü·½¤ñ²v¤£°ª¡AIHC+2/3¤£û{¦h¡A³£·|¼vÅTÃĪ«ªvÀø®ÄªG¡C
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2019/8/20 ¤U¤È 08:11:38
²Ä 1271 ½g¦^À³
|
¦b³oÓª©³o»ò¤[ §Úı±o¤j®a³£¬O¬°·à¤l¦n ©t¨àÃĤj´£ªº¤U¥«¤]¤£¬OÀH«K¶Ã·Q ¦]¬°ªñ¦~¥Í§ÞªÑ¤]¤£¤Ö¤U¥«ªº ¦ý´Nºâ¤U¥«¡A¥un·|¦A¥~¦a¤W¥«¡A¨ä¹ê¤]¤£·|«ç¼Ë ¥un§A¤£½æ¡A¥¦¨ì°ê¥~¤W¥«¡A¤½¥q·|À°§AÂà´«¹L¥h·s¤W¥«¦aªºªÑ²¼
¤£¹L¡A»¡¤F³o»ò¦h §Ú¤]¤£»{¬°¨È·à±d·|¨«³o±ø¸ô ¤@¯ë·|³o»ò°µªº¬O¦]¬°¦b¥xÆWÄw¤£¨ì¿ú(¿³Âd©~¦h) ·à¤l°ê»Ú¦W«×°÷¡AÁÙ¦³ÓADR¦b¬ü°ê µP³£ÁÙ¨SÅu´N´²³õ¨«¤H¬O¤£¥i¯àªº
¥Ø«eªÑ»ù¨«¨ì³o³Ì«nªº ¤£¬O¥þ¤£¥þÃB¥æ³Î¡A¤]¤£¬O¶^°±º¦°± ¦Ó¬O¤G½uÁx¹DÀù¹L¤£¹L ¸¤H¤j¤@ª½Ãöª`ªº¤jªÑªF¬°¦ó±¾¤j½æ³æ³oÂIÅý§Ú¦³¨Ç³\¾á¤ß §Æ±æ²{¦b¥u¬O¾¤©ú«eªº¶Â·t §Æ±æ¤jªÑªF¥u¬O¦]¬°¯Ý¦³¦¨¦Ë¦Ó¦Ñ¯«¦b¦b
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2019/8/20 ¤U¤È 06:12:27
²Ä 1270 ½g¦^À³
|
¸¤H¤j¡A§ÚªºÀç·~û¤µ¤Ñ¥~¥X¡A©Ò¥HµLªk¬d¸ß½æ®a¡A¦ý¬O¤µ¤Ñ¬üªL¤S¶R¶W¡A¥i¬O¦³¼W¥[¤@®aµØ«n¥Ã©÷¤½¸Û½æ¥X100±i¡]¥Ø«e³Ñ¤U1235±i¡^¡An¬Ý©ú¤Ñªºª^³ò¤~¤U©w½×¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/20 ¤U¤È 04:39:15
²Ä 1269 ½g¦^À³
|
To ¤Ñ©R¤j¡A
±z¤§«e´£¨ìªºÓ¤H«Øij¨È·à±d¬O§_¥i¥H¤½§G¥Ø«e¥H²ÖpªºPD¤H¼Æ¡A³oÂI¥i¥H³Ò·Ð±zÄ~ÄòÀ°¦£°lÂܨçó·sª¬ªp¶Ü? ÁÙ¦³¤µ¤Ñ¦³¸òµo¨¥¤H²á¨ì¡A¤U¥«ªº±¡ªp¡A°ò¥»¤W¬O¤£¤j¥i¯àµo¥Í¡A¦pªG¥xÆW³oÃä¤U¥«¡A¨ºADR¤]·|¤@¨Öµ²§ô®ø¥¢¡A³o¹ï¤½¥q¥¼¨Ón¼W¸ê¬O³z¹LADR¼W¸êµo¦æ¬O¤£¤¹³\¥xÆW³oÃä¤U¥«ªº¡A²¦³ºADR¬O®ü¥~¦s°U¾ÌÃÒ¡A°²³]쥻¥i¥HÂà´«ªº¥xªÑ®ø¥¢¤F¡A¨ºADR¤]´N·|¸òµÛ¤]¤U¥«¡A§Ú·Q¤½¥q°£¤F¬Q¤Ñµo¤½§i¡AÀ³¸ÓÁÙ¦³¦A·Q¨ä¥L¹ïµ¦¡A²¦³ºn«ì´_²bȳ̧֪º´N¬O¦³¤@µ§¦¬¤J¡A³o¼Ë¤~¦³¥i¯à¨Ó±o¤Î¦bQ3°]³øµ²ºâ«e«ì´_²bȦb5¶ô¥H¤Wªº¡A§Æ±æ¤½¥q¦AÄ~Äò§V¤O¤F¡C
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/8/20 ¤U¤È 03:27:26
²Ä 1268 ½g¦^À³
|
www.tpex.org.tw/web/stock/3insti/daily_trade/3itrade_hedge.php?l=zh-tw
¤µ¤é¥~¸ê¶R¶W324±i |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/20 ¤U¤È 02:32:37
²Ä 1267 ½g¦^À³
|
To ¥ß§»,
¥i¥H¦A³Ò·Ð±z³oÃäÀ°¦£¬Ý¤@¤U¡A¤µ¤Ñ½æ³æ¬Oþ¨Ç¨é°Ó±¾ªº©O? ¬O§_ÁÙ¬O¨º¥|®a©O? ³Í°ò¡B¸s¯qª÷¹©©µ¥¡B¤j©M°ê®õÁÙ¦³¼¯®Ú¤j³q¡A³Â·ÐÅo!
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2019/8/20 ¤U¤È 02:25:16
²Ä 1266 ½g¦^À³
|
¬Û«H¤j®a³£¬O§Æ±æ¦Û¤vªº§ë¸ê¯à¦³¦nªº¦^À³¡A¤~·|¦³Ó§Oªº·Qªk¡C ¬Ý¬Ý¤µ¤Ñªº¶R³æ¡A¦³³æµ§77±i¸ò248±i¡C ¾ß«K©yªºÁÙ¬O¤j¦³¤H¦b~
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/20 ¤U¤È 12:50:56
²Ä 1265 ½g¦^À³
|
©t¨àÃĤj ¨CÓ¤H³£¥i¥H¦hªÅ½×z¡A¥un¨¥¤§¦³²z¡A§Úª¾¹D§A¬O¬°¤j®a¦n¡A¥u¬O§Aªºµo¨¥·|Åý¤j®a »~¸Ñ¡A¯u¹êªº±¡ªp¬O¤½¥qn¼W¸ê©Î±ÂÅv¡A ¤£·|´î¸ê¡A¤]¨S¦³n¤U¥«ªº³W¹º¡AÁ{§É¶i®i«ö¹w©w®Éµ{¶i¦æ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2019/8/20 ¤U¤È 12:50:49
²Ä 1264 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/20 ¤U¤È 12:49:53
²Ä 1263 ½g¦^À³
|
¤£¤U¥«/¤£n³Q§C»ù¦¬ÁÊ/¤£n§C»ù¨p¶Ò(«Ü¦³¥i¯à)... ¶^¦¨³o¼Ë(¤j¯f),n¦n¤]¤£®e©ö ¼Æ¾ÚÁÙ¨S¥X¨Ó±ÂÅv®e©ö¶Ü¡H¥i¯à¤]n¨ì©ú¦~¡A¤é¤lÃø¼õ
¥[ªo
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/20 ¤W¤È 11:34:37
²Ä 1262 ½g¦^À³
|
¨ä¹êµ¥¤F¨º»ò¤[ªº¤G½uÁx¹DÀùªº¸Ñª¼,Y¯u¨Sµ¥¨ì¦b¥xÆW¤W¥«Âdªº¨È·à±d¨Ó°µ¸Ñª¼µ²ªG,¤ß¸Ì¯uªº·|«Ü¹Ã,©Ò¥H§Æ±æ¦Ñ·à¯à°O¨ú±Ð°V,§Ö§ÖÅý¤½¥qªºªv²z¨B¤J¥¿y,¤£µM§ë¸ê¤H¨C¤Ñ¬Ý¶^°±¹ê¦b¬O¤ßÅåÁx¸õ°Ú~~~~
¥H¤W¨Ñ°Ñ¦Ò.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/20 ¤W¤È 11:00:06
²Ä 1261 ½g¦^À³
|
¹ï©ó (((¨S¦³¨}¤ß))) ¤§»¡ À³¹Dºp
¥[ªo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/8/20 ¤W¤È 10:55:17
²Ä 1260 ½g¦^À³
|
è観¥´¹q¸Ü»P «¸µo¨¥¤H¥æ½Í.
½T»{²Ä¥|©u¸Ñª¼ªº®Éµ{¬O¸g±M®a·|ij¨M©w. ¥¼¨Ó±M®a·|ijY½T»{¸Ñª¼¤é´Á,¤½¥q·|§Y®É¤½§G.
Ó¤H«Øij¨È·à±d¬O§_¥i¥H¤½§G¥Ø«e¥H²ÖpªºPD¤H¼Æ, ¨Ì·ÓÁ{§É¸Ñª¼ ²Ä¤@±ø¥ó ³Ì«á¦¬®×¤H«á3Ó¤ë ©Î ²Ä¤G±ø¥ó,PD ¤H¼Æ¹F127¤Hªº70%=89¤H
Primary Outcome Measures ƒÊ : 1.Incidence of Adverse events (AE) - safety lead-in [ Time Frame: Through 28-days post last study medication administration ] Safety-lead-in: Incidence of AEs, categorized in accordance to CTCAE 4.03 and changes from baseline in safety parameters (including vital signs, ECG parameters, clinical laboratory tests)
2.Objective response rate (ORR) - part 1 [ Time Frame: the later of 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ] Part 1: ORR defined as the proportion of subjects with a best objective response (BOR) of complete response (CR) or partial response (PR), as assessed by an Independent Central Review(ICR) defined by the RECIST v1.1 criteria
3.Progression-free survival (PFS) - part 1 [ Time Frame: The later of 3 months after last subject in or when 70% of the subjects (84 subjects) have experienced a PFS event in Part 1 ] Part 1: Progression-free survival (PFS), defined as the time from randomization until the date of objective disease progression or death (by any cause in the absence of progression). Progression is defined in accordance with the RECIST v1.1 criteria and will be derived programmatically based on data from the ICR of radiological data.
clinicaltrials.gov/ct2/show/NCT03093870?term=aslan001&rank=9
«¸µo¨¥·|¦V¤½¥q°ª¼h¤ÏÀ³.
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/20 ¤W¤È 10:52:48
²Ä 1259 ½g¦^À³
|
To:¥xÁÞ¤j
ªø¤[¥H¨Ó,§Ú©Ò´£¥Xªº·Qªk¸ò¬Ýªk³£¬O¦hªÅ¨Ã³¯,Åý¤j®a°Q½×,±z¦pªGı±o§Ú´£¥Xªº½×ÂI¤£¦n,±z¤]¥i¥H¦Û³Ð¤@ª©¨Ó°Q½×°Ú,¦Ñ·àºÞ²z¶¥¼hºÞ²z¤½¥qªv²z¨ì¥þÃB¥æ³Î,¤£¨ü§åµû,Ãø¹DÁÙnÆg¬ü¥¦¶Ü?§ÚÁÙ¬Oı±o¸Ñª¼¦¨¥\«Ü¦³§Æ±æ,µM´£¥X®`©È¦Ñ·à¦Û¦æ¤U¥«,¥u¬O¤£§Æ±æ¤j®aµ¥«Ý¨º»ò¤[ªº¤G½uÁx¹DÀùªº¸Ñª¼,³Q¤°·h¹B¨«,¦p¦¹¦Ó¤w...
¥»ª©³Ì§Æ±æªº¬O¤j®a¦h¦h°Q½×¦hªÅªº·Qªk,¤×¨ä¬OASLN001ªº¸Ñª¼¹LÃö»P§_,Åwªï¤j®a´£¥X·Qªk³á~~~
¥H¤W¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/20 ¤W¤È 10:52:41
²Ä 1258 ½g¦^À³
|
¨ä¹ê±q6¤ëÀ禬¥X¨Ó¨S¦³¦¬¤J¡A¦³ÂIsenseªº§ë¸ê¤HÀ³¸Ó´Nª¾¹D·|¶^¯}²bȤF¡A©Ò¥HªÑ»ù±q7¤ë¶}©l¤@ª½¶^¶^¤£¥ð¡A¦ý¬O³o®ÉÔ¨ä¹ê½æ¥Xªº¨é°ÓÀ³¸Ó¤w¸g½æ±o®t¤£¦h¤F¡A´Nºâ¤@¯ë§ë¸ê¤H¤£ª¾¹D±µ¤U¨Ó·|Åܦ¨¥þÃB¥æ³ÎªÑ¡A¥L̤â¤Wªº«ùªÑÀ³¸Ó¤]¤£·|¨º»ò¦h¡A¤£¹L³o´X¤Ñªº½æÀ£¡AÂê¦íªº½æ³æ¼Æ¶q¦h±o«Ü¤£´M±`¡A´²¤á¤â¤¤ªº³fþ¥i¯à¨º»ò¦h¡A¨ä¥L¥´¤J¥þÃB¥æ³ÎªºªÑ²¼¤]¨S¹³¨È·à±d³o¼Ë¡A¥[¤W¥ß§»¬Q¤Ñ¥h½ÐÀç·~û¥h¬dªº½æ³æ¡A¤j³£¬O³Í°ò¡B¸s¯qª÷¹©©µ¥¡B¤j©M°ê®õ©M¼¯®Ú¤j³q³o¨Ç¤jªÑªF¡A¤£À´¬°¦ó¥L̲{¦bn³o¼Ë°µ»s³y®£·W¡A¨ä¹ê´²¤áªº½æ³æ¨Ã¨S¦³¨º»ò¦h¡A¤½¥qªº¬ãµo¦¨ªG¤]¨S¦³¥¢±Ñ¡A¸Ñª¼³£ÁÙ¨S¤½¥¬¡A¤£À´³o¨Ç¤jªÑªFªº¤ßºA¬°Ô£n±¾¤j¶q½æ³æ»s³y®£·W¡A¹ï¥L̤]¨S¦n³B§a¡A¥Ø«e¬Ý¨Ó¦X²zÃhºÃ´N¬O§âªÑ»ùÀ£§C¡AÅý¥xªÑ¸òADRªº»ù®t°÷¤j¡A¦]¬°ADR¼W¸ê»ù®æ¬O¬Ý¥xªÑªº¡A©Ò¥H°²³]ADR»ù®æ²{¦b¬O2.6¡A¦Ó¥xÆW³oÃä¬O¤µ¤ÑªÑ»ù12´«ºâADR¬O1.9¡A³o¼Ë¨âÃä»ù®t´N¤w¸g¦³0.7¤F¡A¦Ó¥B¥Ø«e¥xÆW³oÃä½æÀ£ÁÙ¨Sµ²§ôÁÙ¥i¯à§ó§C¡A¥Ø«e¨âÃä»ù®t¤w¸g¹F¨ì36%¥H¤W¡A³o¼Ë¨º¨Ç¤jªÑªF¥h»{ªÑ´N¥i²{ÁÈ36%¥H¤W¡A·íµM³o¬O¥HADRªÑ»ù¤§«á¨SÅܤƤӦh¬°«e´£¡A©Ò¥H¤§«áADR¼W¸ê¬O°Ñ¦Ò¥xªÑ»ù®æ¥h´«ºâªº¡A³o¼Ë»ù®t´N«D±`¥iÆ[¡A¹ï¤jªÑªF¦Ó¨¥¬O¤@µ§¤£¤ÖÀò§Q¡A³o¬O§ÚÓ¤H±À´úªº¡A§_«h¨S¥²n²{¦b¨Ó»s³y®£·W¡AÀ£¦í¥xÆW³oÃ䪺ªÑ»ù¡A¤@ÂI¤ß±o¤À¨É!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G³¯Ë¢¦w10144680 |
µoªí®É¶¡:2019/8/20 ¤W¤È 10:31:59
²Ä 1257 ½g¦^À³
|
§Ú¤ä«ù¥xÁÞ¤jªº»¡ªk¡A¤£nÀ~¤j®a¡C襴¥h¤½¥q¸ß°Ý¬Û«H¤½¥q¤£·|ÀH«K¤U¥«¡C¤j®a³£¬O©¾¹ê¤ä«ùªÌ¡A¤~·|Á«·l³s³s¡A§Ú¤]§ë¸êÃÄ£¹ÃÄ¡Aµ²§½¤@¼ËºG¦r§Î®e |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤ý¥ý¥Í10140379 |
µoªí®É¶¡:2019/8/20 ¤W¤È 10:29:18
²Ä 1256 ½g¦^À³
|
¹ê¦b¬Ý¤£¥X ©t¨àÃĤj ¨º¸Ì¦b»s³y®£¯î ¥u¬O¦b¦^µª«e±ªO¤Í»¡ªº¸Ñª¼«e¤U¥«ªº°ÝÃD¦Ó¥H
¥t¥~²Ä¥|©u¸Ñª¼·|¤£·|¦¨¥\¡A½T¹ê¤]¬Oªñ´Á¦ÜÃö«nªº¨Æ±¡
¨S¹L¦A¦Y´XÓ¶^°±ªO¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/20 ¤W¤È 10:12:40
²Ä 1255 ½g¦^À³
|
©t¨àÃĤj §A¦n¹³¦b»s³y®£·W , ¦Û¤v·íª©¥D°µ¤@¨Ç¨S¨}¤ßªº¨Æ,¦b¤M¤f¤WÅxÆQ, ²{¦bªºªk³W¹ï§ë¸ê¤H«OÅ@¦³ÄY®æ³W©w , ¤£«H¤j®a¥i¥H¥´¹q¸Ü¥h°Ý , «Øij¤£n§â¨S¦³ªº¨ÆÁ¿¦¨¯uªº, ¬Æ»ò®É¶¡¨Ó¤£¤Î ..... ¤p¤ßªk«ß°ÝÃD
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/20 ¤W¤È 09:48:15
²Ä 1254 ½g¦^À³
|
èè¤Wºô¬d¤F¤@¤U,®Éµ{¤WÀ³¸Ó¤£·|¦b¤G½uÁx¹DÀù¸Ñª¼«e´N¯à¦Û¦æ¤U¥«,®Éµ{¨Ó¤£¤Î....©Ò¥H²Ä¥|©uªº¸Ñª¼¦ÜÃö¥Í¦º....
¥H¤W¨Ñ°Ñ¦Ò.. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤ý¸I¥J10148138 |
µoªí®É¶¡:2019/8/20 ¤W¤È 08:44:36
²Ä 1253 ½g¦^À³
|
¦pªG·Ó§A³o¼ËÁ¿ÁÙ¯u¬O®£©ÆÕÙ §Ú³oÀɤW¥«¤]¦³¶R ¬O©âÅÒ©â¨ìªº »{½ß±þ¥X ¬Ý¨ì¶^¨ì³o»ù¦ìÁÙ¯u¬O¶^¯}²´Ãè¤F ¦Y¹L«Ü¦hKY¨t¦CªºªÑ ©Ò¥H²{¦b¥un¬Oky¶}ÀYªº§Ú³£«Ü·P«_
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/20 ¤W¤È 08:18:42
²Ä 1252 ½g¦^À³
|
¨ä¹êµo®i¤¤ªº·sÃĥͧޤ½¥q¨S¤H¦A´î¸êªº,Y¬On´î¸ê¨º¤~¬O¯uªºn¾á¤ß,²{¦b¬Ý¨ÓY¬Oì©l¤jªÑªF¬Ý¦n001ªº¸Ñª¼,ªÑ»ù§CÀÉ°Ñ»P¼W¸êè¦n¥¿ÅªÑ»ù°ª¦ì®ÉªºªÑ¥÷,¦p11(ªñ´Á)+50(«e´Á)=30.5¤¸,³o¼Ë¥L̤~¦³¾÷·|¸Ñ®M°Ú~~
¸Ü»¡¦^¨Ó,§Ú̧ë¸ê¤j²³Ì,«ç»ò·|¹J¨ì³oºØ¶ÆºCªº¥~°êÄê±M®a,©ú©ú²Ä¤@©u¸ê¥»ÃB´N¤w±¼¨ì6.6»õ¤F,ÁÙ¤£¶i¦æ¶Ò¸ê???(³Ì©È´N¬O¥ý«e©Ò´£,¦Û¦æ´£¥X¤U¥«,±aµÛ¸Ñª¼¦¨¥\ªº001¨ì¨ä¥L¦a¤è¤W¥«°Ú!!!)
©Ò¥H¥u¯à¦Û¥ß¦Û±j,¥ý¥´¥hÂd¶R¤¤¤ß°Ý°Ý¹³³o¼Ëªº±¡§Î,§ë¸ê¤HªºÅv¯q¦ó¦b??
¥H¤W¨Ñ°Ñ¦Ò... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/19 ¤U¤È 06:52:48
²Ä 1251 ½g¦^À³
|
1.¨Æ¹êµo¥Í¤é:108/08/19 2.¤½¥q¦WºÙ:¨È·à±dªÑ¥÷¦³¤½¥q 3.»P¤½¥qÃö«Y(½Ð¿é¤J¥»¤½¥q©Î¤l¤½¥q):¥»¤½¥q 4.¬Û¤¬«ùªÑ¤ñ¨Ò:¤£¾A¥Î 5.µo¥Í½t¥Ñ: ¨ÌÃÒ¨é°ÓÀç·~³B©Ò¶R½æ¦³»ùÃÒ¨é·~°È³W«h²Ä¤Q¤G±ø²Ä¤@¶µ²Ä¤@´Ú¡A³Ìªñ´Á°]°È³ø§iÅã¥Ü ²bȤw§C©ó°]°È³ø§i©Ò¦C¥ÜªÑ¥»¤G¤À¤§¤@ªÌ¡C 6.¦]À³±¹¬I: ³z¹L¶Ò¸ê©Î±ÂÅvÂà¥X¼W¥[Àç·~¦¬¤J¤§¤è¦¡§ïµ½¥»¤½¥q²bÈ¡A¥H´Á«ì´_¬°´¶³q¥æ³Î¤§ ¶R½æ¡C¥»¤½¥qì¹wp©ó¤E¤ë´£¥X¶Ò¸êpµe¡A±©¨ü©óÃÒ´Á§½¤Î¥~°ê¤H¶Ò¶°»Pµo¦æ¦³»ù ÃÒ¨é¬ÛÃö·Ç«h¡A¥»¤½¥q¥¼¯à©ó108¦~9¤ë27¤é«e´£¥æ¶Ò¸ê¥Ó½Ð¡C¥»¤½¥q±NP¤O©ó¨ú±oÃÒ´Á §½¤Î¬ÛÃö¥DºÞ¾÷Ãö®Öã¦A«×´£¥æ¶Ò¸êpµe¡C 7.¨ä¥LÀ³±Ô©ú¨Æ¶µ: Åܧó¥æ©ö¤è¦¡¬°¥þÃB¥æ³Î«Y¨Ì¬ÛÃöªk¥O³W©w°õ¦æ¡A´N¥»¤½¥q¤§»{ª¾¡A»P¤½¥qÁ{§É¸ÕÅç ¬ãµo¬¡°Ê¤Î2019¦~²Ä¥|©u¤§TreeTopp¸Ñª¼µ²ªG¨ÃµL¥ô¦óÃöÁp¡C ¨Ì¥»¤½¥q©ó2019¦~8¤ë13¤é¤§·s»D½Z©Ò¤½¥¬¡A¥»¤½¥q¹w´Á©ó2019¦~¤U¥b¦~¹F¦¨¥H¤U ¨½µ{¸O¡G ©ó¤E¤ë©³©ó¼Ú¬w¸~½FÂå¾Ç·|(ESMO) 2019¦~¦~·|µoªívarlitinib¦X¨ÖmFOLFIRI©ó±ß´Á ¹êÅé½F¤§¤@´ÁÁ{§É¸ÕÅç·s¼Æ¾Ú¡C
©ó2019¦~¤U¥b¦~®i¶}ASLAN004©ó¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç¡C
©ó2019¦~²Ä¥|©u¨ú±ovarlitinib¤G½uÁx¹DÀù¥þ²y©Ê¼Ï¯Ã¸ÕÅç(TREETOPP)ªì¨BÁ{§É¸ÕÅç ¼Æ¾Ú¡C
¦¹¥~¡A¤½¥q©ó¤U¦¸¼W¸ê¤§«e¡A¨ÃµL¥ô¦ó´î¸êpµe¡A¯S¦¹»¡©ú¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/19 ¤U¤È 05:10:56
²Ä 1250 ½g¦^À³
|
¬üªL³o®a¥~¸ê³q±`¬O°µµu½uªº¡A¤£¹L°²³]¦pªG¤@ª½³£¬O¶^°±Âꦺ¡A¤£ª¾¬°¦ó¥L²{¦bn¶R¤J¡A¤§«e¬üªL³£¬O°µµu½u¡A¶RÓ¤@¤Ñ¡A¥i¯à¨â¤T¤Ñ«á´N¥þ¥X¤F¡A¤£¹L¨º¨Ç¤j¤áªº½æ³æ¦pªG¤£°h¡A§ë¸ê¤H«ÜÃø¦³«H¤ß¡A°£«D¦³Ô£·s®ø®§¤½§i! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2019/8/19 ¤U¤È 04:59:24
²Ä 1249 ½g¦^À³
|
è¬Ý¤F¤@¤U¡A¤µ¤Ñ175±i¬O¥~¸ê¶Rªº~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¦t10145840 |
µoªí®É¶¡:2019/8/19 ¤U¤È 04:54:51
²Ä 1248 ½g¦^À³
|
¨ä¹ê´N¬Ý¬Ý«á±¬O¤£¬On´î¸ê¸ü¼W¸ê¡A¦pªG¬O¡A¨º·à¤lÁÙ¦³±Ï ¦pªG¤£¬O¡A¨º´N¯uªºÅܾÀ¯È |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/19 ¤U¤È 04:19:46
²Ä 1247 ½g¦^À³
|
¨ä¹ê¾á¤ßªº¬O¤½¥q¦Û¤v¥D°Ê·Q¤U¥« ? ³o¦³¤º½u¥æ©öªº¶ûºÃ~~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/19 ¤U¤È 04:03:08
²Ä 1246 ½g¦^À³
|
To ¥ß§»,
³Í°ò¡B¸s¯qª÷¹©-©µ¥¡B¼¯®Ú¤j³q¡B¤j©M°ê®õ¡A³o¥|®a¨é°Ó¡A¦pªG¤£¬O³Í°ò¤À¦æ¬O³Í°òªº¸Ü¨º´N¬Oì©lªÑªF¡A±q¨È·à±d¤WÂd¤§«á´N¤@¸ô½æªº³Í°ò¡A¦Ó¸s¯qª÷¹©©µ¥¸ò¤j©M°ê®õÀ³¸Ó¤]¬O¬Y¨Ç¤jªÑªF¡A³o¨â®a¤]¬O¤@ª½¦³¦b½æªÑªº¨é°Ó¡A¼¯®Ú¤j³q´N¤ñ¸û©Ç¤F¡A³o®a¬OADR©Ó¿ì¨é°Ó¡A³q±`±q¬ü°êADRÂà´«¨ì¥xÆW¬O³z¹L³o®a¨é°Ó¡A¤£¹L²{¦b¥xÆWªÑ»ù¤ñ¸û§C¡A·|¦³¤H·QÂà¹L¨Ó½æ¶Ü?©Î¬O¤§«eÂà´«¹L¨ÓÁÙ¨S½æ¥Xªº? ¨º³o¼Ë¬Ý¨Ó³o¥|®a³£¬O¤j¤á¡A¤Ï¦Ó´²¤á±¾½æ³æ¤ñ¸û¤Ö¡A³o¼Ë¯uªºÆZ©_©Çªº¡AÃø¹D¬O³o¨Ç¤j¤á¶°©ó¥Î¿ú? ³oÂI´N¤£²M·¡¤F¡A¥H¬°³£¬O´²¤á±¾³æ¡Aµ²ªG³ºµM¬O³o´X®a¨é°Ó¡A쥻³£¦b½æªÑªº¨é°Ó¦A±¾½æ³æ¡A¤£ª¾¥Î·N¬°¦ó?
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2019/8/19 ¤U¤È 03:41:07
²Ä 1245 ½g¦^À³
|
¦U¦ì¤j¤j¡G èè§Ú½ÐÀç·~û¬d¸ß¤@¤U¡A¤µ¤Ñ±¾³æ½æÀ£¬O³Í°ò±¾1544±i¡]³Í°ò±q¥h¦~1¤ë¥÷¶}©l½æªÑ²¼¡A¨ì¬Q¤Ñ¬°¤î¤w¸g½æ¥X7588±i¡^¡A¸s¯qª÷¹©-©µ¥±¾³æ905±i¡]¦ý¬O³o®a¸ò¥»¨S¦³¶R³o»ò¦h±i¡A«ç»ò±¾³æ©O¡H¡^¡AÁÙ¦³¼¯®Ú¤j³q805±i¡A¤j©M°ê®õ600±i¡A¸ß°Ý¤@¤UÀç·~û¡A¦³¥i¯à¬OɧO¤Hªº¨Ó±¾³æ¡A¦Ü©ó¬°¤°»òn¦b³oӮɶ¡ÂI½æ©O¡H
¤U¤È®É¬q¥´¹q¸Ü¥h¤½¥qn§äµo¨¥¤H¡A¦ý¬O¤£¦b¡A¥´¤â¾÷¤]¥¼±µ¡A½Ð°Ý¦U¦ì¤j¤jªº¬Ýªk¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/19 ¤U¤È 02:53:32
²Ä 1244 ½g¦^À³
|
À³µL©Ò¦í¤j 1232½g¿ûÅK¨k¤j¤À¨É¡A¸³¨Æªø¦³440±i¡A°ÆÁ`¨ó²z¦³100±iªº¡A¦³90±iªº¡A¦³69±iªº¡A¦³48±iªº¡A¦³32±iªº... ¨CÓ¤Hªº§ë¸ê¼Ðªº·Qªk³£¤£¤@¼Ë¡A¤£¬O¨C¦ì°ÆÁ`¨ó²z³£¤@©wn¦³«ùªÑ¡A¥x¿n¹qªº°ÆÁ`¤]¦³4Ó¤H¹s«ùªÑ¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡Goldking10148524 |
µoªí®É¶¡:2019/8/19 ¤U¤È 02:47:25
²Ä 1243 ½g¦^À³
|
±q40¦h¨ì²{¦b¤w¸g½ß¤F2/3 ÁÙ¯u¤£ª¾¹D¸Ó«ç»ò¿ì¡A¥u§Æ±æ¤½¥q¥i¥H°µ¨Ç¨Æ¡A¤£nÅý¤½¥q¤U¥«¡AÅý¤pªÑ¥Á¦å¥»µLÂk¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/19 ¤U¤È 02:32:20
²Ä 1242 ½g¦^À³
|
©Ó¤W¤å ¤½¥q³Û¸Ü¦³®Ä¶Ü¡H 1.°ÆÁ` ¨ó²z -->¹s«ùªÑ 2.¨º¤@¦¸ªºªk»¡¤£¬O³£»¡²£«~¦³¦h¦n¡A«H¤ßº¡º¡¡H
§ë¸êªÌ¤£¶R±bªºì¦]¤§¤@À³¬O°w¹ïºÞ²z°ª¼h¡A¦b¤½§i¬ü°êÄw¸ê¨ú®ø«e¡AÃø¹D³£¤£ª¾¹D¹Lµ{¤£¶¶¡A»Ýn¦hºÞ»ô¤U/«B¤Ñ³Æ®×¡H(¥_·¥¬P¬O²{¼W/¨p¶Ò¤@°_°µ)·í¦~¤¤½T©w¨ú®ø«á«o¤Snµ¥¤E¤ë¡A«Ü®t«lªº°õ¦æ¤O¡C
¤µ¤Ñ²Ä¤@½L4±i¡Aªí¥Üµ´¤j¦h¤H¤£·Q½ä¡AÁÙ¦bÆ[±æ ´Á±æ©ú¤Ñ¯à¦³Âà¾÷ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/19 ¤U¤È 02:28:50
²Ä 1241 ½g¦^À³
|
¤WÂdªÑ²¼6291¨K¦ë¤§«e³QÅܧó¥æ©ö ÁÙ¦³¤À½L¤è¦¡¥æ©ö 8¤ë19¤é°_«ì´_´¶³q¥æ³Î ¤w³sº¦¨â¤äº¦°±ªO ,¯f³Ð¤U¤¦~¨Ó·s°ª ,±q¤ë½u¬Ý°_¨Ó´£«e°_º¦, ¤£¬Oµ¥¨ì«ì´_´¶³q¥æ³Î¤~º¦
¤Q¤jªÑªF¸³ºÊ«ùªÑ¦³¤j¶q´î¤Ö¶Ü? ·s¥ô¸³¨ÆªøAndrew James «ùªÑ(440±i) §AªºªÑ²¼¦³¤ñ¥L̦h ?
¤½¥q8/15¤w¤½§i³z¹L¶Ò¸ê©Î±ÂÅvÂà¥X¼W¥[Àç·~¦¬¤J¤§¤è¦¡§ïµ½¥»¤½¥q²bÈ¡A¥H´Á«ì´_¬°´¶³q¥æ³Î¤§¶R½æ ¤½¥q±NP¤O©ó¨ú±oÃÒ´Á§½¤Î¬ÛÃö¥DºÞ¾÷Ãö®Öã¦A«×´£¥æ¶Ò¸êpµe¡C
¬ãµoªº¾AÀ³¯g¦¨¥\¾÷²v¦p¦ó ?
²bÃÒ¥æ©Ò¤ÎÂd¶R¤¤¤ß¤w¬ãÀÀ¤U¥«Âd¾÷¨î¡A¹L¥h¤½¥q²bȬ°t¼Æ¡A¤~·|n¨D²×¤î¤W¥«Âd¡A¥¼¨Ó¹wp±N·s¼W¤U¥«Âd±ø¥ó: 1 ·|p®v»{¬°¦³¤£½T©w«¤j¦]¯À 2 ²bȧC©ó 3 ¤¸ªÌ 3 n¨D§ïµ½Y 3 ¦~¤º¤´µLªk§ïµ½¡A«h·|n¨D¦b¥b¦~«á¤U¥«Âd¡C
¥H¤W¤T±ø¥óѨ¬ 3¦~¥b«á ¤~·|¤U¥« °ÝÃD¬O¤½¥q8/15¤w¤½§i³z¹L¶Ò¸ê©Î±ÂÅvÂà¥X¼W¥[Àç·~¦¬¤J¤§¤è¦¡§ïµ½¥»¤½¥q²bÈ¡A¥H´Á«ì´_¬°´¶³q¥æ³Î¤§¶R½æ , ¥[¤W¥¼¨ÓASLAN001 ASLAN003 ASLAN004 ¤¤¬ü¼Ú¤é ¥|¤j°Ï¶ô¥ô¦ó¤@°Ï±ÂÅv ªÑ²¼²bÈ´N·|¤j´T´£¤É
¤½¥q±NP¤O©ó¨ú±oÃÒ´Á§½¤Î¬ÛÃö¥DºÞ¾÷Ãö®Öã¦A«×´£¥æ¶Ò¸êpµe
°O±o·à¤Í¤w´£¹L¤½¥q·|¦A³z¹LADR ¼W¸ê,Ó¤H»{¬°¦³±ÂÅv´N¤£»Ý¦A³z¹LADR ¼W¸ê,ÁÙ¥¼½Í§´¬°´£°ª²bȤ½¥q·|¦A³z¹LADR ¼W¸ê
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò»P«ä¦Ò¤è¦V
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/19 ¤U¤È 01:42:13
²Ä 1240 ½g¦^À³
|
ªÑ»ù¹ð¯}·s§C ¦Û¯à¦Û§Ú¦w¼¢ ³o¬O ¨C¤Ñ¤@§Q¦h ¦]¬°-->ªÑ²¼¥«³õ±`»¡ »ù®æ§C ´N¬O ³Ì¤jªº§Q¦h ³o¨â¦~ ¯u¬O §Q¦h¤£Â_¡I¡H
¥X¤£¤F ü¡I ¥[ªo§a¡I t³dªººÞ²z·í§½ ½Ð¥X¨Ó³Û³Û¸Ü
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/19 ¤U¤È 01:41:45
²Ä 1239 ½g¦^À³
|
¦Ü20190630¬°¤î¦Ñ·à±b¤W²{ª÷ÁÙ¦³4.66»õ,ªñ´ÁYµL¤jµ§¤ä¥X,¼µ¦ÜASLN001¸Ñª¼¬OÁÙ°÷¥Î,¦ý³o¨ÇÄê¥~°ê±M®a¯à§â¤½¥qªv²z·d¨ì³o¼Ë¹ê¦b¬OÄê³z¤F,³Ì©È³o±N¸Ñª¼¹LÃö¾÷²v°ªªº001·|¦b¥xÆW¤U¥«,µM±a¨ì¥t¤@Ó¦a¤è¤W¥«,³o¼Ë¥xÆW§ë¸ê¤H¯uªº´N°I¨ìÃz.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2019/8/19 ¤U¤È 12:30:52
²Ä 1238 ½g¦^À³
|
¦pªG¥´¥h¤½¥q°Ý¡A·|¦³«ç¼Ëªº¦^À³¡H |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/19 ¤U¤È 12:06:13
²Ä 1237 ½g¦^À³
|
¥[ªo¤£¤U¥h¤F
¤£¬Ý¤£ª¾¹D ¤@°ï¨ó²z ¸g²z ¹s«ùªÑ °ÆÁ`¯Å¤]¤Öªº¥i¼¦ Ãø¹D ÅQ¥D¯Å XX»õ¬üª÷»ùÈ-->¤£ª¾¹Dn³{§C¶R?
ª©¤W°ª¤â°ª°ª¤â¤@ª½¤@ª½¤£Â_¥Î¤ß«´_Po¤åÀ³ÂX¤j¤O«× ¥ý³ê¿ô¤º³¡¤H§ë¸ê ®¾¦^ÀZ¶Õ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤ý¥ý¥Í10140379 |
µoªí®É¶¡:2019/8/19 ¤W¤È 11:40:21
²Ä 1236 ½g¦^À³
|
¨Æ¹ê¤W¬O«Ü¦³¥i¯à¤U¥«ªº¡AµM«á¿ï¨ä¥Lªº°ê®a¦A¤W¥«¡A¦Ü©ó¤U¥«¹ï»OÆWªºªÑªF ©Ò³y¦¨ªº¼vÅT ¥_·¥¬Pª©³£¤w°Q½×¨ìÄê¤F
·íµMÁÙ¬O¤@©w·|¦³¤H¥X¨ÓÅ@¦æ¡A»¡¤£·|¡KµM«á·|ºë¯«³Û¸Ü¡A¦ý¥¿±`ªÑ»ù¨ì³oÓµ{«×¡A¤S¥´¤J¥þÃB¥æ³ÎªÑ¡A¤U¥«ªº¥i¯à©Ê¬O¤j¤@ÂI
°£«D¤½¥q¦³¤@¤°»ò¤@©wn¯d¦b»OÆW¥«³õªº²z¥Ñ¡C¤]¨S·Q¨ìªÑ¤ý¥_·¥¬PªºªÑ»ù²×©óÁÙ¬O¤S¶W¶VªÑ¦Z¨È·à±d¤F¡A
¥u¬O¨S¦³·Q¨ì·|¥H¦p¦¹ªº¤è¦¡¶W¶V¡A¦bªÑ»ù³£§Ö¶^¯}¤Qªº®ÉÔ ¬Û·|
¯¬¤j®a³£ÁÈ¿ú |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¦N¦Ì10148522 |
µoªí®É¶¡:2019/8/19 ¤W¤È 11:23:07
²Ä 1235 ½g¦^À³
|
¨È·à±d-KY¦b¥xÆW¤U¥«?¯uªº·|¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/19 ¤W¤È 10:37:52
²Ä 1234 ½g¦^À³
|
³Ì©È³o¨ÇÄê³f¥~°ê±M®anÅý¨È·à±d-KY¦b¥xÆW¤U¥«,µM«á¦b¨ä¥L¦a¤è¤W¥«,¤j®aı±o¦³¥i¯à¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/19 ¤W¤È 09:57:03
²Ä 1233 ½g¦^À³
|
¨º¨S¬Æ»ò,¥u¬OADRªº¦«ºÞ»È¦æ,§Æ±æ²H°¨¿ü©ÎMerck§Ö¥X¨Ó¼W¸ê§a,µM«á§â³o¨ÇÂi±¤Wªº¹Î¶¤´«±¼§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¿ûÅK¨k¤l10144826 |
µoªí®É¶¡:2019/8/19 ¤W¤È 09:51:54
²Ä 1232 ½g¦^À³
|
¨È·à±d-KY(6497)¸³ºÊ¨Æ¸g²z¤H¤Î¤jªÑªF«ùªÑ©ú²Ó ¸ê®Æ¤é´Á:108/07 ¿ï¥ô¤é´Á:108/06/21 ¾ºÙ¡¶ ©m¦W/ªk¤H¦WºÙ «ùªÑ±i¼Æ¡¶ «ùªÑ¤ñ¨Ò ½è©ã±i¼Æ ½è©ã¤ñ²v ¿W¥ß¸³¨Æ Robert E. Ho 0 0.00% 0 0.00% ¿W¥ß¸³¨Æ ®]¼y¾W 0 0.00% 0 0.00% ¸³¨ÆÝÁ`¸g²z ³Å«i 0 0.00% 0 0.00% ¸³¨Æªø Andrew James 440 0.27% 0 0.00% ¸³¨Æ BV Healthcar(ªÑ)-ªL®¶½÷ 7,542 4.71% 0 0.00% ¸³¨Æ Alnair Inves-§dÂ@ 8,824 5.51% 0 0.00% ¸g²z ©g³· 0 0.00% 0 0.00% ¸g²z ¶À«Ø¾± 0 0.00% 0 0.00% ¸g²z ¼ïÀR©É 0 0.00% 0 0.00% °ÆÁ`/°]·|¥DºÞ Kiran Asarpo 69 0.04% 0 0.00% °ÆÁ` Alain Benjam 100 0.06% 0 0.00% °ÆÁ` Stephen Doyl 0 0.00% 0 0.00% °ÆÁ` Mark McHale 0 0.00% 0 0.00% °ÆÁ` ©PÄ×½¬ 48 0.03% 0 0.00% °ÆÁ` Á§Ӷh 90 0.06% 0 0.00% ¨ó²z ù¿p¤å 24 0.01% 0 0.00% ¨ó²z ³¯ªY©y 6 0.00% 0 0.00% ¨ó²z «¸¥ç´Ð 0 0.00% 0 0.00% ¨ó²z ¿½°¶ÄP 0 0.00% 0 0.00% ¨ó²z Alison Ward 0 0.00% 0 0.00% ¨ó²z Isana Endo 32 0.02% 0 0.00% ¤jªÑªF Kimba Capita(¦³) 3,344 2.09% 0 0.00% ¤jªÑªF Ma Ong Kee 3,191 1.99% 0 0.00% ¤jªÑªF Manbant Inve(¦³) 3,191 1.99% 0 0.00% ¤jªÑªF Guan Yu Chan 4,255 2.66% 0 0.00% ¤jªÑªF Match Point 1,432 0.89% 0 0.00% ¤jªÑªF Maybank Kim(ªÑ) 54 0.03% 0 0.00% ¤jªÑªF Milestone He(¦³) 5,310 3.31% 0 0.00% ¤jªÑªF Naga Capital(¦³) 2,804 1.75% 0 0.00% ¤jªÑªF ¤W®ü¤dÆk³Ð·~(¦³) 1,064 0.66% 0 0.00% ¤jªÑªF ¤¤°ê«H°U°Ó·~ 4,527 2.82% 0 0.00% ¤jªÑªF ¬ü°Ó¼¯®Ú¤j³q 30,000 18.72% 0 0.00% ¡¯¨Ó¦Û¦~³ø©M¤½¶}»¡©ú®Ñªº¤jªÑªF¸ê®Æ¡A¬O«üªÑÅv¦û«e¤Q¦WªºªÑªF¡CY·í¤¤¤jªÑªFè¦n¬O¡G¸³¨Æ¡BºÊ¹î¤H¡B¸g²z¤H¡B«ù¦³ªÑ¥÷¶W¹L¦Ê¤À¤§¤QªÑªF¡A·|¨Ì·Ó¤½¶}¸ê°TÆ[´ú¯¸¤Wªº¨C¤ë§ó·s¸ê®Æ¡C ¡¯«ùªÑ±i¼Æ¡A«ö«ù¦³ªÑ¼Æ¥|±Ë¤¤J¦Ü±i¼Æ¡C ¡¯«ùªÑ±i¼Æ¤Î¤ñ¨Ò¦b¤½¥q¿ì²z²{ª÷¼W¸ê®É¸³ºÊ¨Æ«ùªÑ«Y¥H¼W¸ê»{Áʪº¤ñ¨Ò¥h¦ôºâ¡A¥¼¥²»P¹ê»Ú±i¼Æ¤Î¤ñ¨Ò¬Û²Å¡C ¡¯¸ê®Æ¨Ó·½: ¥xÆW¸gÀÙ·s³ø
³Ì¤U±¤@Ó¤jªÑªF? ¯u?°²?
¨ÓÀY¯u¤j |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤ý¸I¥J10148138 |
µoªí®É¶¡:2019/8/19 ¤W¤È 09:51:33
²Ä 1231 ½g¦^À³
|
¬Ý¨ì¨È·à³o¼Ë¯uªº¤ß§N£¸¥b⋯ ¤S£¸°¦·sÃĪѨI¤U¥h¤F ¬Ý¨ì³o¼Ë´N·Q¨ì§Ú§ë¸êªºÃÄxÃÄ ´NºâÀ£¹ï®³¨ìÃÄÃÒ¤F¤S«ç¼Ë ÁÙ¤£¬OºG½ß ¥xÆW·sÃĪѯuªºÁÙ¦³«Üªø£¸¬q®É¶¡n¿i£«⋯⋯ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¦t10145840 |
µoªí®É¶¡:2019/8/19 ¤W¤È 09:42:41
²Ä 1230 ½g¦^À³
|
³o¤@ÀɬݨӤSnª±´î¸ê¦b¼W¸ê³o©Û¤F¡A¤£µM¹ê¦b·Q¤£¨ì¤½¥qn«ç»ò±Ï²bÈ¡A«áÄò¹êÅç¤]ÁÙ¬On°µ¡A´î¸ê±Ï²bÈ¥~¡A«áÄò¶Ò´Ú¤]®e©ö¡AÃø©Ç¤jªÑªF¤§«e¤@ª½½æ¡A®Ú¥»¤£¬O¤W±ªº¤£³B²z¡A¤jªÑªF¥ý½æ¤@½æ¡Aµ¥«Í¾î¹M³¥ªº®ÉÔ¦b¶i³õ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/19 ¤W¤È 09:41:42
²Ä 1229 ½g¦^À³
|
¬Ý¤@¤U¸³ºÊ¨Æ¸g²z¤H¤Î¤jªÑªF«ùªÑ©ú²Ó¡AÅܰʤ£¤j¡A¼¯®Ú¤j³q«ù¦³30000±i
èè¤@µ§175±i³Q¦³²´¥úªº§ë¸ê¤H¶R¨«
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GºCºC¶]10142302 |
µoªí®É¶¡:2019/8/19 ¤W¤È 09:33:16
²Ä 1228 ½g¦^À³
|
´IÂd200«ü¼Æ¦¨¤ÀªÑ8/26°_§R°£¨È·à±d-KY (108/08/19 08:44:26) ¦³Ãö¥»¤¤¤ßÂd¶R¡u´IÂd200«ü¼Æ¡v¦¨¤ÀªÑ²§°Ê¡C
¤½ §i ¨Æ ¶µ¡G
¤@¡B¦¨¤ÀªÑ§R°£¤§ÅܰʥͮĤé¡G108¦~8¤ë26¤é¡C
¤G¡B¦¨¤ÀªÑ§R°£¡G¨È·à±d-KY(¥N¸¹¡G6497)¡C
¨Ì³W©wn²M,µ¥«Ý¦n¤ß¤H±µ¤â
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/19 ¤W¤È 09:17:49
²Ä 1227 ½g¦^À³
|
ª½±µ¥s³Å«i¥X¨ÓÁ¿¦n¤F,¦]¬°§äµo¨¥¤H¤]¨S¥Î(©Î³\¥L´N¬O¨ü®`ªÌ),³o¨Ç©Ò¿×¥~°ê¥ÕÄê±M®a...ü,Å¥»¡¥xÆW¤º³¡³oÃ䦴N´£¥X·|¦³¥þÃB¥æ³Îªº°ÝÃD,¤WÀY¤£²z~~~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/19 ¤W¤È 09:10:05
²Ä 1226 ½g¦^À³
|
ADR¤jº¦ ADR¤jº¦... ¬Ý¤£¨ì»ùȪº¥Ñ50 40 30 20...³°Äò½æªº·|«á®¬·|«á®¬....
ÅQ¥D¯Å XX»õ¬üª÷»ùÈ ¨Ó¤@Ó¥O¤HÆf¥Ø/º}«Gªº±ÂÅv ¥þÃB¥æ³Î¥æ©ö¤p¨Æ¤@¼Î °í«ù¤U¥h °í«ù¤U¥h ¥[ªo ¥[ªo ¥[ªo
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/19 ¤W¤È 08:52:03
²Ä 1225 ½g¦^À³
|
¤µ¤Ñ¬Ý¨Ó¥xÆW³oÃ䪺§ë¸ê¤H¤S®£·W¤@°ï¤H±ÆµÛ½æªÑ²¼¡Aı±o¤½¥q¥i¯àn¥X¨Ó»¡©ú¤@¤U¶Ò¸êªº¶i«×¤ñ¸û¦n¡AÅý§ë¸ê¤H¯à¦w¤ß¡A§_«h¬ãµoµ²ªGÁÙ¨S¥X¨Ó¡A«ü¥ÜÅܧó¥æ©ö¤è¦¡¡A¤j®a³£³QÀ~µÛ«æµÛ©ß°â¡A³o¼Ë¤£ª¾¦ó¦~¦ó¤ë¤~¥i¥H¤î¶^¤F! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/18 ¤W¤È 12:15:56
²Ä 1224 ½g¦^À³
|
«Ó°¶¤j ¦pªG¬O³o¼Ë´N¤è«K¦h¤F¡A¥u®t¨â¤Ñ§Q®§¡A²{¦b¬¡¦s§Q²v¨º»ò§C¡A§Q®§·L¤£¨¬¹D |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2019/8/17 ¤U¤È 09:32:00
²Ä 1223 ½g¦^À³
|
²{¦b¶R¥þÃB¥æ³ÎªÑ¦n¹³¨S¦³³o»ò³Â·Ð §Ú°Ý§Ú¨é°Ó ¥un¤áÀY¤º¦³¨¬°÷ªº¿ú´N¥i¥H¶R¤F |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/17 ¤U¤È 03:57:14
²Ä 1222 ½g¦^À³
|
è¶}©l¤£²ßºD¡A¶R¤@¦¸´N·|ı±o¤]¨S¦³·Q¹³ªº¨º»òÃø¡A¨ä¹ê¤]¥i¥Hµ¥¸Ñ°£Åܧó¥æ©ö¦A¶R¡A¥u¬O§AµLªk´£«e¥d¦ìÀ³ÅÜ¡A¨ì®ÉÔ¥i¯à¤wº¦¤@¤j¬q¤F¿ù¥¢¨}¾÷¡A¸Û¦pROGER5889¤j©Ò¨¥©ú¤Ñ·sÃÄ»ùÈ·|Åý±z¶R¤£¤U¤â!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2019/8/17 ¤U¤È 03:04:43
²Ä 1221 ½g¦^À³
|
ÁÂÁÂ¥xÁÞ¤j¤À¨É ì¨Ó³o»ò³Â·Ð §Ú²Ä¤@¦¸¶R¨ì¥þÃB¥æ³ÎªÑ 쥻¥H¬°¥un¥æ³Î户¸Ì¿ú°÷´N¥i¥H¶R ¯à¥Îapp¶RÁÙ¬O¤ñ¸û¤è«K |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/17 ¤U¤È 01:34:51
²Ä 1220 ½g¦^À³
|
¤@¯ëÁʶRªÑ²¼¤è¦¡: ¥´¹q¸Üµ¹Àç·~û ºô¸ô¤U³æ ²{³õ¤U³æ µ¥
ÁʶRÅܧó¥æ©öªÑ²¼: ¥´¹q¸Üµ¹Àç·~û ¨BÆJ¦p¤U
1.¥´¹q¸Ü°Ý§AªºÀç·~û¥æ³ÎªÑ´Ún¦s¤Jªº¨é°Ó«ü©w¤áÀY±b¸¹ (¥æ³Î´Ú¤£¬O¦s¤J쥻ÃÒ¨é¥æ³Î¤áÀY )
2 ÁʶRÅܧó¥æ©öªÑ²¼¤£¯à«e¤@¤Ñ¦s¤J, ¥u¯à·í¤Ñ¦s¤J, ¥i¥ÎATMÂà (°Ý¤@¤UÀç·~û¨é°Ó«ü©w¤áÀY±b¸¹Âà±b¤W¬O¦h¤Ö?)
3.¦s¦n¤§«án§iª¾Àç·~û§A¦s¤J¦h¤Ö¿ú, n¶R xxªÑ²¼ »ù¦ì ¦s¤J¦h¤Ö¿ú¯à¶R´X±i (Àç·~û»P«á¥x½T»{´Ú¶µ¤§«á´N¥i¥H¤U³æ) ( °Ý¤@¤UÀç·~û ²{³õ¦s¤J¥æ³ÎªÑ´Ú ²{³õ¤U³æ¬O§_¥i¥H ? )
4 Y¨S¶R¨ì·í¤Ñ¿ú·|°h¦^§AªºÃÒ¨é¥æ³Î¤áÀY ¶R¨ì´N·|¦©ÃÒ¨é¥æ³Î´Ú , ¦h¦s·|°h¦^¨ìÃÒ¨é¥æ³Î¤áÀY
5½æ¥XÅܧó¥æ©öªÑ²¼ªÑ: ¥´µ¹Àç·~û, Àç·~û·|¥ý½Ð«á¥x°µ ¡§°é¦s¡¨, «á·|½Ð«á¥x¤Hûkey³æ ½æ¥X¸û²³æ ! ¥´¹q¸Ü´N¦æ¤F, ¸ò¤@¯ë½æªÑ²¼µ{§Ç¤@¼Ë!
Á`¤§ ÁʶRÅܧó¥æ©öªÑ²¼³z¹LÀç·~û´N¹ï¤F ½æ¥XÅܧó¥æ©öªÑ²¼ªÑ ¸ò¤@¯ë½æªÑ²¼µ{§Ç¤@¼Ë!
¥H¤W¬O¬d¨ìªº¸ê°T¤À¨É ¦³¿ù½Ð§ó¥¿ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2019/8/17 ¤W¤È 08:04:47
²Ä 1219 ½g¦^À³
|
¸¤H¤j¤j¡G ¥xÆW§ë¸ê¤H³£¬O³Q¤ÀªR®vÀ~¦ºªº¡A«Ü¦h¤ÀªR®v¥u·|Å@µÛ¦Û¤vªº»{¾iªÑ¡A´N°Û°I¨ä¥¦ªºªÑ²¼¡A¤j®a¥[ªo§a~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/17 ¤W¤È 07:54:39
²Ä 1218 ½g¦^À³
|
¤ñ°_¥xÆW³oÃä¡A¬ü°êªº§ë¸ê¤HÁÙ¤ñ¸û¦³«H¤ß¡AADR¬Q¤Ñ¦¬½L»ù2.93´«ºâ¥x¹ô»ù®æ18¶ô¦h¤F¡A½L«á¥æ©ö¬Æ¦Ü¦³¨ì3.9ªº»ù®æ¡A´«ºâ¥x¹ô»ù®æ24¶ô¦h¤F¡A§Ú·Q´N¬O¤@Ó«H¤ß°ÝÃD¡A¥xÆW³oÃäÅܦ¨¥þÃB¥æ³Î¡A¦ý¬O¬ü°ê¨ºÃäÁÙ¬O¥¿±`¥æ©ö¡A¤@¼ËªºªÑ²¼¥u¦]¬°¥æ©ö¤è¦¡§ïÅÜ´NÀ³¸Ó®t¨º»ò¦h¶Ü¡H¨ä¹ê¤£À³¸Ó¤£¹L®£·WÁÙ¬O·|Åý§ë¸ê¤H®`©È¡AY¥i¥H§Æ±æ¤½¥q¯à»¡©ú¤@¤U¤½¥qn¶Ò¸êªº¤è¦¡¥Ø«eªº¶i«×¦bþ¡H±ÂÅv®×¦pªG¦]¬°«O±K±ø´Ú¤£¯à¤½¶}¡A¤]¯à»¡©ú¤@¤U¬O§_¦³¦b¶i¦æ¬¢½Íªº¡AÁö»¡ÃÄ«~¨S¦³·s¶i«×¥i¥H¤½§i¡A¤£¹L¯à»¡©ú¤@¤U¤½¥q¥¼¨Óªº¸êª÷¨Ó·½ª¬ªpÅý§ë¸ê¤H¦w¤ß¤]¬O¥i¥H¦Ò¼{¶i¦æªº¡A²¦³º¨È·à±d±q¥h¦~°ªÂI64¤@¸ô¤U¶^¨ì¬Q¤Ñ14.75¡AªÑ»ù¶^¤F§Ö80%¡A¤]¬O¸Ó·QÂI¤èªkÅý§ë¸ê¤H¯à¹ï¤½¥q§ó¦³«H¤ß¡A¦Ó¤£¬O®£·Wªº©ß°âªÑ²¼¡A¤@ÂIÂI¤p¤p«Øij¡I |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/8/16 ¤U¤È 11:37:50
²Ä 1217 ½g¦^À³
|
¤µ¤ÑªÑ²¼½æ¥X¤â¬O14.75ªº»ù®æ¡A©ú¤Ñ·sÃÄ»ùÈ·|Åý±z¶R¤£¤U¤â!
¸`¿ý¤½¥qºô¶ASLAN004ªº P1aµ²ªG»¡©ú: ¥Ñ©óASLAN004Âê©wªº§@¥Î¾÷Âà»Pdupilumab¬Û¦ü¡A§Ú̬۫HASLAN004±N¥i´`»P¨ä¬Û¦üªº¼f¬d¬yµ{¨Ã¦¨¬°¦P¯Åº¨£ªºIL-13R£\1§í¨î¾¯¡K.ASLAN004¥i±æ´£¨Ñ [¾¯¶q¸û§C]»P [¥ÎÃÄÀW²v¸û§C] ¤§µ¹ÃĤ覡¡A´î¤Ö¯f±wªºt¾á¡C¦¹¥~¡AASLAN004ªº¿ï¾Ü©Ê¸ûdupilumab¨Î¡A¦]¦¹§Ú̬۫HASLAN004¤Þ°_ªº°Æ§@¥Î¥i±æ¸ûdupilumab»´·L¡C
---¤jP¸ò³o½g¾Ç²z¬ã¨s¦¨ªG§k¦X:www.ncbi.nlm.nih.gov/pmc/articles/PMC4553078/ (.DupilumabÂê©wIL-4R£\µ²¦X,ASLAN004Âê©wIL-13R£\1,³£¯àªýÂ_ IL-4 ¤Î IL-13, ¥u¬Oµ²ºc¾÷¨îªº±µ¦X¦¸§Ç¬Û¤Ï)
....These findings demonstrate that the IL-13R£\1 chain is required for signaling by IL-4 in fibroblasts but not in macrophages; however, in the case of IL-13, the IL-13R£\1 chain is essential for signaling by both macrophages and fibroblasts. Interestingly, we observed that the magnitude of STAT6 activation and gene expression induced by IL-4 in wild-type macrophages is generally greater than that induced by IL-13. These results are consistent with related findings by others [19, 20]
¡K.IL-4 receptor structural studies have shown that IL-4 and IL-13 catalyze differential assembly of IL-4 receptor complexes [40, 41]. IL-4 binds initially to the IL-4R£\ chain to generate a binary complex which then recruits either £^c or the IL-13R£\1 chain to form ternary type I or type II IL-4 receptor complexes respectively. In contrast, the primary ligand-binding chain for IL-13 is IL-13R£\1, not IL-4R£\. Consequently, IL-13 binds initially to the IL-13R£\1 chain to generate IL-13/IL-13R£\1 binary complexes which then recruit the IL-4R£\ chain to complete assembly of ternary type II IL-4 receptor complexes. Therefore, IL-4 and IL-13 induce rapid assembly of type II IL-4 receptor complexes by catalyzing physical association of the same receptor chains (i.e., IL-4R£\ and IL-13R£\1), but the order of assembly is reversed. Although the receptor assembly sequences are distinct for IL-4 and IL-13, the intracellular signal transduction pathway and repertoire of genes induced by these two cytokines are largely the same. ¡K.IL-13R£\1 was essential for signaling by both IL-4 and IL-13 in fibroblasts. ¡K¡KIL-13 is a primary regulator of airway hyper-reactivity and mucus production in allergic lung inflammation, and it has been shown to play a more dominant role than IL-4 as an effector cytokine of Th2-mediated pathogenesis in several animal models
macrophage¥¨¾½²ÓMªº¨ä¤¤¤@Ó«n¨¤¦â¬O²¾°£ªÍ¤¤ªºÃa¯j¸H¤ù¤Î¹Ð®J¡C¥t¥~¡A¦bºC©Êª¢¯g¤¤¡A²¾°£¤w¦º²ÓM¥ç¬°«n¡C¦bª¢¯gªº¦´Á¡A¤j¶qªº¶Ý¤¤©Ê²y·|¦û¾Ú±w³B¡C·í³o¨Ç²ÓM¦º¥h®É¡A´N·|³Q¥¨¾½²ÓM©ÒÄá¨ú¡C fibroblast¦¨ÅÖºû²ÓM¦b³\¦hÅÖºû¤Æªº¯e¯f¤¤°_«n§@¥Î¡A¦pªÍÅÖºû¤Æ¡BµÇÅÖºû¤Æ¡B©Mµw¥Ö¯f¡C
[·|û¡GROGER588910148151 µoªí®É¶¡:2019/8/14 ¤W¤È 08:42:00²Ä 1194 ½g¦^À³ ASLAN004(IL-13R£\1)¦A¥[ºò¸}¨B,¨È·à±d«Ü¦³¾÷·|¦¨¬°COPDÅQ¥D!]++++¯dÓ¬ö¿ý«Ý¹Ú·Q¹ê²{¼y¯¬!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/16 ¤U¤È 10:30:18
²Ä 1216 ½g¦^À³
|
¥ß§»¤j °£«D«æ»Ý¥Î¨ì¿ú, §_«h¦b·¥§CÂI½æ±¼·|¤£·|´XÓ¤ë«á«á®¬?! ·Pı¤µ¤Ñµê±¾½æ³æ¤£¤Ö, ³Q®£Äß±±¨î»´©ö½æ¥XÁo©ú¶Ü ? è°Ñ¦Ò§Þ³N¤ÀªRªº®Ñ¦³´£¨ì¥X²{²Ä¤TÓ¸õ X ¯Ê¤f n¦p¦ó ?
ªÑ»ù¤£¬Oµ¥¨ì«ì´_´¶³q¥æ³Î¤~¶}©lº¦,¤@¦³¦n®ø®§´N·|¦³¹w´Á¤ÏÀ³ , ·à¤l¤w§¹¦¨varlitinib¤G½uÁx¹DÀù¦¬®× ¥¼¨Ó¬ãµo¶O¥Î¶}¤ä±N¤j´T¤U°, ¥[¤Wºë²¤H¤O¶}¤ä, Varlitinib »P ASLAN003 ¤w±ÂÅv«nÁú BioGenetics °£¤F¤w¦¬¤JªºÃ±¬ùª÷¥~,¥¼¨Ó¾P°â»P¬ãµo¨½µ{ª÷¦Xp¦³¬ù1900¸U¬ü¤¸¦¬¤J³o¨Ç¦¬¤J·|Åý²bȤW¤É, ¤é¥» ¼Ú·ù ¤¤°ê ¬ü°ê ¥ô¦ó¤@°Ï±ÂÅvñ¬ù»P¨½µ{ª÷ ·|Åý¨CªÑ²bȦA¤£Â_¤W¤É
¨È·à±d-KY ¤½¥¬ 2019 ¦~²Ä¤G©u°]°È·~ÁZ¤Î§ó·s¬ãµo¶i«× ¨ä¤¤ASLAN003 ·¥´Iµo®i¼ç¤O
ASLAN003 ©ó´_µo/Ãøªv©Ê«æ©Ê°©Åè©Ê¥Õ¦å¯f¤G´Á²Ä¤@³¡¤À¸ÕÅç¤w§¹¦¨¦¬®×¡A¥H³æ¿WªvÀø¤§¤è¦¡´ú¸Õ ASLAN003 ¥|ºØ¤£¦P¾¯¶q(100mg QD¡B200mg QD¡B100mg BID¡B200mg BID)¤§Àø®Ä¡C©PÃä¦å²GªÞ²ÓM¼Æ ¥Ø¤j´T°§C¹F 98%¡A¨Ã¦b¼Æ¦ì¯f±w¤¤Æ[¹î¨ìªÞ²ÓM¦bµu®É¶¡¤º¤U°¡AASLAN003 ©ó«æ©Ê°©Åè©Ê¥Õ¦å¯f ¯f±w¦³¨}¦n@¨ü©Ê¡A24 ¦ì¨ü¸ÕªÌ¤¤¥u¦³¤@¦ì¥X²{³QÂkÃþ¬°¸ÕÅçÃÄ«~¬ÛÃöÄY«¤£¨}¨Æ¥ó¤§¶Ý¤¤©Ê¥Õ¦å²y §C¤Uµo¿N»P¸~½F·»¸Ñ¯gÔ¸s
¥þ²y«æ©ÊÅè²ÓM¥Õ¦å¯f¥«³õ»P¬ü°ê¯f¤H¼Æ (The Global Market for Acute Myeloid Leukemia, 2019 to 2024 )
«n¼Æ¾Ú½Ķ ¥þ²y«æ©ÊÅè²ÓM¥Õ¦å¯f¥«³õ¦b2018¦~ªº»ùȬ°7.016»õ¬ü¤¸¡A¦ôp2024¦~ªº»ùȬ°15.39»õ¬ü¤¸¡A½Æ¦X¦~¼Wªø²v¬°14¢H¡C Áx¹DÀù¥þ²y¥«³õ14»õ¬ü¤¸ ( ³o¨âÓ¾AÀ³¯gªº¥þ²y¥«³õ·|¤ñX ¸Î¤w¤W¥«ªºÃÄ¥«³õ¤j¦h¤F, ASLAN004 ¾AÀ³¯g²§¦ì©Ê¥Ö½§ª¢ ¥«³õ§óÃe¤j, ¥un¦³Ävª§¤O ¤£©È¨S¥«³õ )
¬ü°êÀù¯g¨ó·|¹ï¬ü°ê2019¦~¥Õ¦å¯fªº¦ôp «æ©ÊÅè©Ê¥Õ¦å¯f¡]AML¡^·sµo¯f¨Ò¼Æ¬ù¬°21,450¨Ò¡A¨ä¤¤¤j³¡¤À¤H¤f¬°¦¨¤H¡C ¦ôp¤j¬ù10,920¤H¦]AML¦Ó¦º¤`¡C
¥þ²yAMLµo¯f²vªº¤W¤É¥H¤Î¥Ñ©ó¸Ó¯e¯f¾ÉPªº¦º¤`²v¼W¥[¡A¹wp±N¹ïAMLÀøªk²£¥Í¥¨¤j»Ý¨D¡A±q¦ÓÂX¤j¥þ²yAML¥«³õ¡C
¥_¬ü¥Ø«e¦b«æ©ÊÅè©Ê¥Õ¦å¯f¥«³õ¦û¾Ú¥D¾É¦a¦ì¡A¨Ã¦³±æ¦b¥¼¨Ó´X¦~Ä~Äò¨ä¾ÚÂI¡C¬ü°ê¥e¦³³Ì¤jªº¥«³õ¥÷ÃB¡C¬ü°ê¦bµo¹F°ê®a¤¤¾Ö¦³¿W¯SªºÂåÀø«O°·¨t²Î¡C
2016¦~¡A¬ü°êÀù¯g¨ó·|¦ôp¬ù¦³21,380¨Ò·sµo«æ©ÊÅè©Ê¥Õ¦å¯f¡]AML¡^¯f¨Ò©M¤j¬ù10,590¨Ò¬ü°êAML¦º¤`¯f¨Ò¡C
¤w¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2019/8/16 ¤U¤È 06:56:41
²Ä 1215 ½g¦^À³
|
¥xÁÞ¤j¡G¤µ¤Ñ¦³5®an¦C¤J¥æ³ÎªÑ¡A¦ý¬O¥u¦³¨È·à±d¶^°±ªO¡A¦³¤@ÀÉÁÙº¦°±ªO¡]¤Ñ½µ¡^¡A¯uªº·d¤£À´§ë¸ê¤H¨ì©³¦³¨S¦³¬Ý¨ì¨È·à±dªº¼ç¤O¡A¤@°ï¤H¥u·|¸òÀHµÛ§O¤H±þ§C°l°ª¶Ü¡H¦U¦ì¤j¤j¥[ªo§a~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/16 ¤U¤È 03:59:48
²Ä 1214 ½g¦^À³
|
¤WÂdªÑ²¼6291¨K¦ë¤§«e³QÅܧó¥æ©ö ÁÙ¦³¤À½L¤è¦¡¥æ©ö 8¤ë19¤é°_«ì´_´¶³q¥æ³Î ¤µ¤éº¦°±ªO ,³Ð¤U¤¦~¨Ó·s°ª ,±q¤ë½u¬Ý°_¨Ó´£«e3Ó¤ë°_º¦, ¤£¬Oµ¥¨ì«ì´_´¶³q¥æ³Î¤~º¦
¨È·à±d¬O¦³¥»½è¦³¼ç¤Oªº¥Í§ÞªÑ¤£·|³Q®I¨S ²×±N´¬Ü¦R®ð
¤w¤W¤À¨É ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/16 ¤U¤È 02:37:06
²Ä 1213 ½g¦^À³
|
To ±áÄf,
¨È·à±d·|¸òCSL«Ã±¦X¬ù¡A¦]¬°¤§«e¨È·à±d¨Ã¨S¦³004ªº¥þ²y°Ó«~¤ÆªºÅv§Q¡A«Ã±¹LÃö©óASLAN004©ó©Ò¦³¾AÀ³¯g¤§¥þ²y¶}µo¡B»s³y»P°Ó«~¤ÆÅv§Q³o¨Ç³£´x´¤¦b¤â¤¤¡A®Ú¾Ú×qªº¦X¬ù¡A¨È·à±d-KY±N©óASLAN004¤T´Á¸ÕÅç±Ò°Ê®É¤ä¥ICSLºµ§´Ú¶µ3,000¸U¬üª÷¡CCSL±N¥i¦¬¨ú³Ì°ª¹F9,500¸U¬üª÷¤§¥Ó½Ð¶i«×¨½µ{ª÷¡B³Ì°ª¹F6.55»õ¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü10%¤§Åv§Qª÷¡Cn¨ì004¤w¸gn°µ¤T´Á¤~»Ýnµ¹¥Iñ¬ùª÷µ¥¾P°â¤À¼í¡A¨ì¤F¤T´Á¤§«e¥i¯à¨È·à±d¦´N±ÂÅvµ¹¦n´XÓ°ê®a¤F¡A©Ò¥H¤£·|¦³¸êª÷ªº°ÝÃD¡A¦Ó³ÌªñªÑ»ù¤@ª½¶^¡A«h¬O¦]¬°¼W¸êªº®Éµ{¨S¦³»°¤W°]³ø¤½¥¬²bÈn«·spºâ¡A©Ò¥H§ë¸ê¤H¾á¤ßªÑ²¼nÅܧ󬰥þÃB¥æ³ÎªÑ¡A©Ò¥H¤~·|±q7¤ë¶}©lªÑ»ù´N¤@ª½¶^¶^¤£¥ð¡A¶W¹L400±i¥H¤WªºªÑªF«ùªÑ¥e¤ñÁÙ¬O¦³77%¥H¤W¡A¤½¥q¤]¨S¦³©ñ¥ôªÑ»ù¤@ª½¶^¡A¥L̸Ӥ½§iªºÁÙ¬O³£¦³¤½§i¡A¥[¤W·sÃĤ½¥q¤£¤j¥i¯à¹ê¬I®wÂêѤ§Ãþªº¡A¦³¬ãµo¸êª÷ªº»Ý¨D¡A¥Ø«e¥u¯à´Á«Ý±ÂÅv®×µo¥ÍÁÙ¦³ADR¼W¸ê»°§Ö¥Ó½Ð°e¥ó³q¹L§a!
Thanks, |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G±áÄf10141758 |
µoªí®É¶¡:2019/8/16 ¤U¤È 12:13:46
²Ä 1212 ½g¦^À³
|
³oÀY°×½¾©Ç©Çªº ºM¼W¸ê ¨S¿úÁÙ»PCSL´£°ª»ù½X ²{¦b©ñ¥ô¥L¶^.... ¤Ï¥¿µ¥³o¶g«ùªÑÅܤƴNª¾¹D¤F.... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/16 ¤W¤È 11:11:30
²Ä 1211 ½g¦^À³
|
§Úı±o¬O³o¨Ç©Ò¿×¦Ñ·à¥~°ê±M®aªº¹ï¤½¥qªv²zªº¶ÆºC,ÁÙ¦nASLN001¦b²{¶¥¬q¤G½uÁx¹DÀù³Óºâ°ª,¤]³\µ¥ì©lªÑªF¥X¿ú¬O³Ì§Ö²æÂ÷¥þÃB¥æ³Îªº¤èªk.. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p©ú10146339 |
µoªí®É¶¡:2019/8/16 ¤W¤È 10:19:58
²Ä 1210 ½g¦^À³
|
Åܧó¥æ©ö¬O¨Æ¹ê¡A¦ýÓ¤H¨Ã¥¼¬ÝÃa·à¤l¡C ¤@¼Ë³£¬O¶R¼Ö³z¡]µLªk¹wª¾¸Ñª¼µ²ªG¡^¡A ªá14¸Uµ¥2-3¦~ªº¯Eô¡A©Mªá1.47¸Uµ¥4Ӥ몺·à¤l¡AÓ¤Hı±o·à¤l¨ä¹ê¬O«Ü¦Eºâªº®@¡I ¥u¬O±¼¤U¨Óªº¤M¤l¤£n¾ß¡Aµ¥¯uªº¦³¤j¶q¥´¶}ªº®ÉÔ¡A¦A¨Ó¦@Á¸²±Á|§a¡I¦]¬°¨ºÓ®ÉÔ¡A´Nºâ¤j¶q¥´¶}¬O°²ªº¡A¤]«Ü®e©ö³]°±·lÂIªº¡C |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2019/8/16 ¤W¤È 09:49:25
²Ä 1209 ½g¦^À³
|
ÁÂÁ¸¤H¤jªº»¡©ú¡A¤@°_¥[ªo§a~ |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¸¤H¥d¯S10145479 |
µoªí®É¶¡:2019/8/16 ¤W¤È 09:29:36
²Ä 1208 ½g¦^À³
|
¥Ø«e¬Ý¨Ó«e¤@°}¤lªº½æÀ£¡AÀ³¸Ó³£¬O©È¨È·à±dÅܦ¨¥þÃB¥æ³ÎªÑ¨Óªº¡A¨ä¹ê·sÃĤ½¥qªì´Á¬ãµo¤@ª½¦b¿N¿ú¡A¨S¦³¦¬¤J¥u¦³¤ä¥X³o¼Ë¤½¥qªº²bȶ^±o«Ü§Ö¡A¨È·à±d²bȳ̰ªªº®ÉÔ¬O¦b¥h¦~Q2¦³10¶ô¦h¡A¨º®ÉÔÁÙ¥i¥H²{ªÑ·í¨R¡A±µ¤U¨ÓQ3¤»¶ô¦h¡BQ45¶ô¦h¨ì¤µ¦~Q1¤¶ô¥XÀY¡A¦³ÂIsenseªº§ë¸ê¤H¥un¬Ý¨ì6¤ëÀ禬¥X¨Ó¡Aµo²{¨È·à±dQ2¨S¹³Q1¦³±ÂÅv¶i±bÁÙ¦³¨ä¥L¶Ò¸êºÞ¹DÄw±¹¸êª÷¡AÀ³¸Ó´N¥i¥H±À¥XQ2²bÈ·|¶^¯}¤¶ô§a¡A©Ò¥HQ2¨È·à±d¦bºM¦^¶Ò¸ê®×ªº®ÉÔ¡A¨º¤ÑªÑ»ù´N¶^«Ü¦h¡A±q¨º®ÉÔ¶}©l¨È·à±d¨C¤Ñªº½æÀ£´N«Ü°ª¡A¤§«eÁÙ¦³¤j¤áÀ°¦£¼µ½Lºû«ùªÑ»ù¦b20¶ô¡A«á¨Ó¼µ¤£¤U¥hªÑ»ù´N¤@¸ô¤U®À¤F¡A¥Ø«e¬Ý¨ÓÓ¤H»{¬°¤½¥q¥i¯à¦b³o²bȤè±À³Åܤñ¸ûºC¡A¤]¥i¯àpºâªº¤Óè¦n¤Ó¦³¦Û«H¤F¡A©Ò¥H»{¬°¥unQ2¼W¸ê¦¨¥\¡A²bÈ°¨¤W´N·|¦^¤É¤£¤Ö¡A¤£¹L¨S·Q¨ì¥xÆW¸ò¬ü°ê¦b¼W¸ê®×©w»ùµ¦²¤ªºÃö«Y¡AÅý¨È·à±d¨M©wºM¦^¼W¸ê®×¡A´N¬O»ù®t¤£°÷¤j¤£¯à§l¤ÞADRªº§ë¸ê¤H©Ò¥HºM¦^¡A¦ý¤]Åý¥xÆW³oÃä²bȶ^¯}¤¤¸¡AÅܦ¨¥þÃB¥æ³ÎªÑ¡A·íµMADR¨ºÃ䪺¤è¦¡¬O¤£¨ü¼vÅTªº¡AÅÜ¥þÃB¥æªÑ¤§«á¶R½æ´NÅܪº¤ñ¸û³Â·Ð¤F¡A©Ò¥H¤µ¤Ñ¤@¶}½Lª½±µÄé¨ì¶^°±»ù¦ì¡AÁÙ¤@°ï½æ³æµ¥µÛ½æ¡A²{¦b¥u¯à¬è¨DQ3´Á¶¡¯à¦³±ÂÅv®×©Î¬O¨ä¥Lªº¶Ò¸ê¤è¦¡¡A»°§ÖÅý²bȦ^¤É¡A§_«h´NºâQ4¸Ñª¼¦¨¥\¡A¨ü¥þÃB¥æ³ÎªÑÃö«Y¡A¥i¯à§ë¸ê¤H»{¬°¶R½æ³Â·Ð¡A¤]¤ñ¸û¤£·|¶i³õ¶RªÑ¤F¡AÁ`¦Ó¨¥¤§¡AÁÙ¬O§Æ±æ¸Ñª¼¦¨¥\¡A¸ò¤j®a³Ì´Á«Ýªº±ÂÅv®×»°§Öµo¥Í§a!
¨È·à±d ¥[ªo! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥ß§»10147985 |
µoªí®É¶¡:2019/8/16 ¤W¤È 08:51:23
²Ä 1207 ½g¦^À³
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/15 ¤U¤È 11:26:20
²Ä 1206 ½g¦^À³
|
¨È·à±d¤µ±ß10ÂI48¤À´£¥X¦]À³±¹¬I: ³z¹L¶Ò¸ê©Î±ÂÅvÂà¥X¼W¥[Àç·~¦¬¤J¤§¤è¦¡§ïµ½¥»¤½¥q²bÈ¡A¥H´Á«ì´_¬°´¶³q¥æ³Î¤§ ¶R½æ
5.¦]À³±¹¬I: ³z¹L¶Ò¸ê©Î±ÂÅvÂà¥X¼W¥[Àç·~¦¬¤J¤§¤è¦¡§ïµ½¥»¤½¥q²bÈ¡A¥H´Á«ì´_¬°´¶³q¥æ³Î¤§ ¶R½æ¡C¥»¤½¥qì¹wp©ó¤E¤ë´£¥X¶Ò¸êpµe¡A±©¨ü©óÃÒ´Á§½¤Î¥~°ê¤H¶Ò¶°»Pµo¦æ¦³ »ùÃÒ¨é¬ÛÃö·Ç«h¡A¥»¤½¥q¥¼¯à©ó108¦~9¤ë27¤é«e´£¥æ¶Ò¸ê¥Ó½Ð¡C¥»¤½¥q±NP¤O©ó¨ú ±oÃÒ´Á§½¤Î¬ÛÃö¥DºÞ¾÷Ãö®Öã¦A«×´£¥æ¶Ò¸êpµe¡C
mops.twse.com.tw/mops/web/index |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2019/8/15 ¤U¤È 10:18:24
²Ä 1205 ½g¦^À³
|
½Ð°Ý©ú¤ÑÁÙ¯à±b¤á¨S¿ú¶R·à¤l¶Ü? |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/15 ¤U¤È 07:47:18
²Ä 1204 ½g¦^À³
|
¤WÂd¤½¥q¤µ¦~Q2°]°È³ø§i§Î¦¡¼f¾\µ²ªG¥XÄl
¡e°OªÌ³¯¬X㸡þ¥x¥_³ø¾É¡fÂd¶R¤¤¤ßªí¥Ü¡A¤WÂd¤½¥q108¦~«×²Ä¤G©u°]°È³ø§i§Î¦¡¼f¾\¤µ¡]15¡^¤é§¹¦¨¡A®Ú¾Ú¼f¾\µ²ªG¡A¤WÂd¦³»ùÃÒ¨éÀ³Ä~Äò°±¤î¥æ©öp¦³1®a¡AÀ³½Õ¾ã¥æ©ö¤è¦¡p¦³7®a¡A¨Ã¦Û108¦~8¤ë19¤é°_¹ê¬I¡C
~~¼W¬°Åܧó¥æ©ö¤èªk¤§¤½¥q¦³¤Ñ½µ¡]2740¡^¡B³Í¬f¹ê·~¡]3073¡^¡B©M¶i¡]3191¡^¡B¤Ñ´¡]5345¡^¡B¨È·à±d-KY¡]6497¡^¡C¥D¦]¬°108¦~«×²Ä¤G©u°]°È³ø§iÅã¥Ü²bȤw§C©ó©Ò¦C¥ÜªÑ¥»¤G¤À¤§¤@¡A¬G·s¼W¬°Åܧó¥æ©ö¤èªk¡C
±ÂÅv±ÂÅv±ÂÅv ¥[ªo¥[ªo¥[ªo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G«Ó°¶10144972 |
µoªí®É¶¡:2019/8/15 ¤U¤È 04:09:31
²Ä 1203 ½g¦^À³
|
¤ä«ù·à¤l¨â¦~¦h ¤w¸g¨Ó¨ì§Y±NÅuµP¨M¾Ô¤§»Ú ¬ÝªÑ»ù¦p¦¹®z¶Õ¡A¤ß¤¤¤]¤£§K¾á¼~ ¥u§Æ±æ·à¤l¬OÀY¶¯·à¡A¤£n¬O¯f¿ß |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/15 ¤U¤È 02:01:23
²Ä 1202 ½g¦^À³
|
§ë¸êªÌ·íµMÃö¤ß¥æ©ö¤è¦¡/¤½¥q²{ª÷¬y¶q/.../·íµMÁÙ¦³±ÂÅv
¤@¯ëÄw¸ê³£»Ýn3~6Ó¤ë¤~¯à§¹¦¨ Á{§ÉÄ~Äò°µ Ä~Äò¿N¿ú Q3/¦~©³¤S³Ñ¦h¤Ö¡H ¦~¤¤¨ú®øÄw¸ê¨ì²{¦b¤@ÂI°ÊÀR³£¨S¦³ ¤£¯Ê¿ú¡H ÁÙ¬O §Y±N¤jµ§ªº±ÂÅvª÷¨ÓÓµØÄRÂà¨--¦Ñ¯«¦b¦b ÁÙ¬O ¤£´±·Qªº´N·|....--Â÷³õÆ[±æ ¯¬ºÖ©Ò¦³ªÑªF
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/15 ¤W¤È 11:42:23
²Ä 1201 ½g¦^À³
|
ÁÂÁ¤p©ú¤jªº¤À¨É ¤WÂd¤½¥q¨CªÑ²bÈ < 5 ¤¸ ¥u»Ýn1©u¨CªÑ²bÈ > 5 ¤¸ ªÑªFÅv¯q¼W¥[´N¥i¥H«ì´_´¶³q¥æ©ö «ÂI¤£¦bÅܧó¥æ©ö¤è¦¡ ¦Ó¦b¼Æ¾Ú¥¿± ±ÂÅv¥X¥h ¬O²bȤj´T¤Éªº«nÃöÁä
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p©ú10146339 |
µoªí®É¶¡:2019/8/15 ¤W¤È 09:52:17
²Ä 1200 ½g¦^À³
|
¥xÁÞ¤j±z¦n¡A§C©ó5¤¸¡A¨Ì¾Ú¤WÂd³W©w¡A´N¬OnÅܧó¥æ©ö¤èªk¡]¹w¦¬´Ú¨é¡^¡A¤]´N¬O¥þÃB¥æ³Î®@¡I¡]Âd¶R¤¤¤ß·~°È³W«h²Ä12±ø³W©w¡^ ¦ü¥GµL¶·¦A¤©¦Ò¼{·|p®vªº·N¨£¡C ÂԨѰѦҡI |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G©t¨àÃÄ10140658 |
µoªí®É¶¡:2019/8/15 ¤W¤È 09:04:56
²Ä 1199 ½g¦^À³
|
ASLN001-¤G½uÁx¹DÀù¸Ñª¼°ß¤@ªº·ÀI¶È¦³¹ï·Ó²Õ¬°¥¼PDªº¤H¼Æ¶W¥G¹w´Áªº¦h,¦ý¥ý«eª©¤W¤j¤jªº¤ÀªR¤Îªk»¡·|³ø§i(PFS¶È¦³3Ó¤ë)³£¦b¦b»¡©ú¹ï·Ó²ÕPFS¤£¥i¯à¤Ó°ª,¬G¹w´Á³Ó²v°ª,¥B«iô¹wp²Ä¥|©u¤~¸Ñª¼,¥[¤W®É¶¡©¹«á¹êÅç²Õ¥¼PD®É¶¡©Ôªøªº¦]¯À,³Ó²v«ùÄò»¼¼W·í¤¤....
¥H¤W¨Ñ°Ñ¦Ò... |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/8/15 ¤W¤È 07:29:07
²Ä 1198 ½g¦^À³
|
1.¤½¶}¸ê°TÆ[´ú¯¸://mops.twse.com.tw/mops/web/t163sb01 ¦X¨Ö°]°È³ø§i-·N¨£ºØÃþ¡GµL«O¯dµ²½×/·N¨£-- ¦X¨Ö°]°È³ø§i§ó(¸É)¥¿¡GµL (¤WÂd¤½¥q)¨È·à±d-KY ¢°¢¯¢·¦~¤W¥b¦~«×°]°È³ø§i
2.ð«n¬À»P±i¤l¤å³Ð«ØªºTANOX¤½¥q¡A¹Lµ{10¤À¨¯W¡A¤]´X«×µo¥Í¸êª÷±µªñ¬\·²ªºµ~ª¬¡A3¦¸¦^¥x¶Ò¸ên³]¥ß³J¥Õ½èÃļt¡A ¤j¤@·sÂA¤H¤O¥DÀÁ¸m¦¹®×¡A²z¥Ñ¬O:¥«³õ³W¼Ò¤£¤j¡BÃÄ«~»ù®æ¤Ó¶Q¡A½a¤H¶R¤£°_¡B¨S¦³¥«³õ¼ç¤O.(³o¨Ç²z¥ÑѦb·sÂA¤H¦V ¸g«Ø·|ªº³ø§i¸Ì)---²{¦b¤¤¸Î¦b·s¦Ë¦Û«Ø³J¥Õ½èÃļt¡A¤S½ð¤S¿å¤j¤@·sÂA¤H!
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/14 ¤U¤È 11:34:10
²Ä 1197 ½g¦^À³
|
¤W¥«¤WÂd¤½¥q¸gÀç¤@¬q®É¶¡«á¡A¦]°]°Èµo¥Í¦M¾÷¥HP²£¥Í°h²¼±¡§Î¡A©Î¬O¥¼¦b³W©w®É¶¡¤º¤½§i¨C¤@©uªº°]°È³øªíµ¥¦]¯À¡A±N·|¨Ì³W©w³Q¦C¬°¡u¥þÃB¥æ³ÎªÑ¡v Y¨CªÑ²bȧC©ó5¤¸¡B·|p®v¬d®ÖñÃÒ·N¨£¦³¡u«DµL«O¯d·N¨£¡v©Î¹ï¡uÄ~Äò¸gÀç°²³]¦³ºÃ¼{¡vµ¥¡AªÑ²¼±N¦C¬°¡u¥þÃB¥æ³Î¡vµ¥Åܧó¥æ©ö¤è¦¡¡C
¨È·à±d¤WÂd¥H¨Ó¦]¨S¦³°]°Èµo¥Í¦M¾÷©Î°h²¼±¡§Î,¦b³W©w®É¶¡¤º³£¦³¤½§i¨C¤@©uªº°]°È³øªí ÁöµM¨CªÑ²bȧC©ó5¤¸¡B¦ý·|p®v¬d®ÖñÃÒ·N¨£¨S¦³¡u«DµL«O¯d·N¨£¡v©Î¹ï¡uÄ~Äò¸gÀç°²³]¦³ºÃ¼{¡vµ¥ Ó¤H»{¬°¨È·à±dªÑ¤£·|¦C¬°¥þÃB¥æ³ÎªÑ
¥Í§Þ¤½¥q³£¦b¿N¿ú,§C²bȬO«Ü´¶¹Mªº²{¶H, °ê®anµo®i¥Í§Þ²£·~¤]ª¾¹D³o¨Ç±¡ªp ,¥un¥¿¬£¸gÀç²Å¦X¬ÛÃö³W©w ¤£·|³Q¦C¬°¥þÃB¥æ³ÎªÑ
¨Ò¦p¥_·¥¬P2016¦~ Q2 ¨CªÑ²bÈ 3.3¤¸ 2017 Q3 ¨CªÑ²bÈ 1.04¤¸ (¦³²Å¦Xªk³W ¨S¦³¦C¬°¥þÃB¥æ³ÎªÑ)
www.wantgoo.com/stock/report/basic_bvps?stockno=6550
¥H¤W¬OÓ¤H§ä¨ìªº¸ê®Æ ¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤p¦t10145840 |
µoªí®É¶¡:2019/8/14 ¤U¤È 10:59:00
²Ä 1196 ½g¦^À³
|
¦³¨S¦³¤j¤j¥i¥H¸Ñ´b¤@¤U ³oÀÉ·|¤£·|Åܦ¨¥þÃB¥æ³ÎªÑªü ªÑ»ù¨S°_¦â n²{¼WÁÙ¬O¥h°ê¥~§äª÷¥D¨p¶Ò³£¤£®e©ö§a |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/14 ¤U¤È 03:45:08
²Ä 1195 ½g¦^À³
|
Äг½n½¨¤F¶Ü¡H
ÅQ¥D¯Å XX»õ¬üª÷»ùÈ ¨Ó¤@Ó¥O¤HÆf¥Ø/º}«Gªº±ÂÅv
¥[ªo ¥[ªo ¥[ªo |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/8/14 ¤W¤È 08:42:00
²Ä 1194 ½g¦^À³
|
ASLAN004(IL-13R£\1)¦A¥[ºò¸}¨B,¨È·à±d«Ü¦³¾÷·|¦¨¬°COPDÅQ¥D!
1.2016ªº¤å³¹ www.nature.com/articles/mi201556 ....IL-13 receptor (R) £\1 and are key pharmacological targets in fibrotic diseases. However, the roles of IL-13R£\1 in mediating lung injury/repair are unclear........ These data highlight underappreciated protective roles for IL-13R£\1 in lung injury and homeostasis.
2. But COPD is different, and Schleifer said Regeneron doesn¡¦t have a ¡§high degree of confidence in Dupixent¡¦s ability to conquer that disease.
Researchers saw ¡§clear-cut effects¡¨ in Dupixent¡¦s asthma studies, but ¡§COPD is much tougher,¡¨ Schleifer said. Regeneron¡¦s not giving up on the indication, ¡§but we wouldn¡¦t rank this as something we have high degree of confidence in,¡¨ he said.
¡§COPD is a very complex disease,¡¨ echoed Yancopoulos. Many patients who have COPDs worsened with other Type 2 inflammations, and ¡§the problem is finding the right patients to treat, and also negotiating with the FDA who likes to study cleaner diseases,¡¨ he explained. COPD is indeed a tough nut to crack, previous studies have shown. Dupixent¡¦s biologics competitors, GlaxoSmithKline¡¦s Nucala and AstraZeneca¡¦s Fasenra, have both turned up failure in the field. |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/8/14 ¤W¤È 07:03:08
²Ä 1193 ½g¦^À³
|
¤@³õ¥@¬ö¤jÁɺVÆr¤F!!! ¥Ò¶¤:¨È·à±d+CSL,ASLAN004 ¤A¶¤:ù¤ó+Dermira, Lebrikizumab ¤þ¶¤:Dermira+ Almirall¼Ú¬w°Ï, Lebrikizumab
¤A¶¤/¤þ¶¤¹ï»ù»P¹ê¤O²¤¶: ù¤óªºlebrikizumab(anti-IL13)¬O·½¦Ûð«n¬À»P±i¤l¤å³Ð«ØªºTANOX¤½¥qªºTNX650. www.immunwork.com/edcontent_d.php?lang=tw&tb=1&id=20
1.DermiraÀò±où¤ó¥Ö½§¯fÃĪ«Lebrikizumab¿W®a¶}µoÅv zi.media/@yidianzixun/post/sJwWwt 2.20190319:¥Íª«¬ì§Þ¤½¥qDermira(DERM.US)¥Ö肤ª¢ªv疗试验¨ú±o¬ð¯} ªÑɲ涨¶W80% 3.Almirall hands over $50M for European rights to Dermira¡¦s Dupixent challenger www.fiercebiotech.com/biotech/almirall-hands-over-50m-for-european-rights-to-dermira-s-dupixent-challenger |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/13 ¤U¤È 11:34:00
²Ä 1192 ½g¦^À³
|
¨È·à±d-KY ¤½¥¬ 2019 ¦~²Ä¤G©u°]°È·~ÁZ¤Î§ó·s¬ãµo¶i«×
¥H¤U¬OÓ¤H¤À¨É¡G
A Ó¤H»{¬°³æ¤@¾¯¶q»¼¼W¸ÕÅ礧µ²ªGÅã¥Ü ASLAN004 @¨ü©Ê¨}¦n¡A¥i§¹¥þ§í¨î¤U´å¤¶½è¡A¥ÎÃľ¯¶q¤Ö,¥ÎÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸, Äâ±aÀx¦s¤è«K, ¦w¥þ©Ê°ª¡@°Æ§@¥Î§C¡@·¥´I¯S®íÄvª§¼ç¤O
B 2019 ¦~¤U¥b¦~®i¶} ASLAN004 ©ó¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç, ©ú¦~§¹¦¨¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç±N¥i¬Ý¨ìÀø®Ä,¥Ñ©ó³oÁûÃĪº¯S®íÄvª§¤O,¯f±w¤H¤f¼ÆÃe¤j,·mn±ÂÅvªº¥Í§Þ¤½¥q¥²µM¦h,¡@§¹¦¨¤@´ÁÁ{§É±ÂÅvªº¾÷·|¤j, ¨Ì¾Ú105¦~«×¦~³ø¤ÀªR¤@´Á±ÂÅv±ÂÅv¨½µ{ª÷·|¤ñ¤G¤T´Á¦h¡@( ¤@¢Ý¤¦~«×¦~³ø 72¡Ð73 ¶¡@¡^
C¯S©w°Ï°ì»P¯e¯f¤§±ÂÅv¥æ©ö®×¥ó¡G¦^ÅU¥ý«eªº±ÂÅv¥æ©ö®×¡A¦pªGÃĪ««YÄÝ°ª«×¥¼³Qº¡¨¬ªºÂåÀø»Ý¨D¡A»sÃĤ½¥qÄ@·N¤ä¥I¤jµ§ª÷ÃB¥H¨ú±oÓ§O¥«³õ©Î°Ï°ì¥«³õ±ÂÅv¡A¦Û 2009 ¦Ü2016 ¦~²Ä¤T©u¡A¤j«¬»sÃĤ½¥q¨ú±o¨ãµo®i¼ç¤OÃÄ«~¤§«D¥þ²y©Ê±ÂÅv¦@p14 ¥ó¡A³o¨Ç¥æ©ö®×¦b¤½¶}¥«³õ¦¨¥æª÷ÃB¤¶©ó 3.32 »õ¦Ü 4.44 »õ¬ü¤¸¤§¶¡¡A¥§¡Ã±¬ùª÷¬° 1.08 »õ¬ü¤¸¡A¨½µ{ª÷¬° 5.6 »õ¬ü¤¸¡C( ª`·N¬Ý¬O«D¥þ²y©Ê±ÂÅv ¡^¡@¡@(¤@¢Ý¤¦~«×¦~³ø 72¡Ð73 ¶¡@)
D ASLAN003 ¥|ºØ¤£¦P¾¯¶q(100mg QD¡B200mg QD¡B100mg BID¡B200mg BID)¤§Àø®Ä¡C©PÃä¦å²GªÞ²ÓM¼Æ¥Ø¤j´T°§C¹F 98%¡A¨Ã¦b¼Æ¦ì¯f±w¤¤Æ[¹î¨ìªÞ²ÓM¦bµu®É¶¡¤º¤U°¡AASLAN003 ©ó«æ©Ê°©Åè©Ê¥Õ¦å¯f¯f±w¦³¨}¦n@¨ü©Ê¡A24 ¦ì¨ü¸ÕªÌ¤¤¥u¦³¤@¦ì¥X²{³QÂkÃþ¬°¸ÕÅçÃÄ«~¬ÛÃöÄY«¤£¨}¨Æ¥ó¤§¶Ý¤¤©Ê¥Õ¦å²y§C¤Uµo¿N»P¸~½F·»¸Ñ¯gÔ¸s¡@(Àø®Ä·¥´I¼ç¤O¦w¥þ©Ê°ª¡^
¢Ó Ó¤H»{¬°ASLAN001, ASLAN003¡@, ASLAN004 ÄÝ°ª«×¥¼³Qº¡¨¬ªºÂåÀø»Ý¨D¡A2020¦~ASLAN003 §¹¦¨¤G´Á,ASLAN004§¹¦¨¤@´ÁÁ{§É´N·|±ÂÅv¡]·à¤l³oºØ¤p«¬¥Í§Þ¤½¥q¤£·|¿Ë¦Û°µ¤T´ÁÁ{§É¡^, ASLAN001¤G½uÁx¹DÀù±ÂÅv¡]¼Æ¾Ú¤½§i«e«á³£¦³¥i¯à¡^
F 2019¦~²Ä¥|©u¨ì2020¦~¬O¨È·à±d±K¶°±ÂÅv¦~,§¹¦¨¤@Ó±ÂÅv®×¥ó´N·|¦b¬ãµo¤U¤@Ó²£«~, ¦p¹L±Ó®ð³Ý , COPD ASLAN001¤@½uÁx¹DÀù ©Î¨ä¥LÀù¯gµ¥....¡@
¥H¤W¤À¨É¡@¶È¨Ñ°Ñ¦Ò |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/13 ¤U¤È 10:37:51
²Ä 1191 ½g¦^À³
|
¨È·à±d-KY ¤½¥¬ 2019 ¦~²Ä¤G©u°]°È·~ÁZ¤Î§ó·s¬ãµo¶i«×¡@
2019 ¦~ 8 ¤ë 12 ¤é¡A·s¥[©Y ¡V »EµJ©óÁ{§É¶¥¬q¸~½F¤Î§K¬Ì¾Ç¤§Á{§É¶¥¬q¥Íª«»sÃĤ½¥q¨È·à±d-KY (NASDAQ:ASLN, TPEx:6497)¤µ¤é¤½¥¬ºI¦Ü 2019 ¦~ 6 ¤ë 30 ¤é¤§©u«×°]°È³ø§i¥H¤Î³Ì·sÁ{§É¬ãµo¶i«×¡C ¨È·à±d-KY °õ¦æªø³Å«i³Õ¤hªí¥Ü:¡u¨È·à±d¦b²Ä¤G©u¨ú±o¤F«¤j¶i®i¡A¥]¬A§ÚÌ»P K-MASTER q©w¦X§@¶}µo varlitinib ©óÂಾ©ÊGÀù¤§¨óij¡B§ó·s¶i¦æ¤¤ªº ASLAN003 «æ©Ê°©Åè©Ê¥Õ¦å¯f¸ÕÅçµ²ªG¥H¤Î©ó ASLAN004 ³æ¤@¾¯ ¶q»¼¼W¸ÕÅç¨ú±oµ²ªG¡AÅã¥Ü»P¨ä¥L IL4/IL13 §í¨î¾¯¬Û¤ñ¯à°÷«P¶i²ÓM¤À¤Æ¡Cų©ó¤Wz¥O¤H¹ª»Rªº·s¼Æ¾Ú¡A§Ú ̶i¦Ó»P CSL ×q¨óij¡AÂX®i¨óij½dÃ¥¨ú±o³o¶µ²§¦ì©Ê¥Ö½§ª¢¦P¯Åº¨£ªvÀø§ÜÅ餧¥þ²y¶}µo¡B»s³y»P°Ó«~¤Æ Åv§Q¡C®i±æ¤U¥b¦~¡A§Ú̹wp©ó²Ä¥|©u¨ú±o varlitinib ©óÁx¹DÀù¤G½u¼Ï¯Ã©Ê¸ÕÅç(TreeTopp)¤§ªì¨B¼Æ¾Ú¡C¡v 2019 ¦~²Ä¤G©u©Mªñ´Á·~°È«GÂI
Á{§É¬ã¨sµo®i
Varlitinib • ¨È·à±d-KY »P Korean Cancer Diagnosis & Treatment Enterprise (K-MASTER)ñ¸p¨óij¡A¶i¦æ varlitinib ¦X¨Ö¨C©P¤@¦¸ paclitaxel ©ó HER1/HER2 ¦@¦Pªí²{¡B±ß´Á©ÎÂಾ©Ê¤G½uGÀù¤§ 1b/2 ´Á¦h¤¤¤ß³Ê§Î¸ÕÅç¡A¦®¦b µû¦ôÃĪ«¦w¥þ©Ê©M¦³®Ä©Ê¡C³o¶µ¶}©ñ©Ê¡B¦h¤¤¤ß¸ÕÅç±N©Û¦¬¬ù 400 ¦ì¨ü¸ÕªÌ¡A¨Ì¥Íª«¼Ð°O¯S©Ê¤À¬° 4 Ó¸ÕÅç²Õ¥H¤Î¤@²Õ¹ï·Ó²Õ¡C
ASLAN003 ( • ASLAN003 ©ó´_µo/Ãøªv©Ê«æ©Ê°©Åè©Ê¥Õ¦å¯f¤G´Á²Ä¤@³¡¤À¸ÕÅç¤w§¹¦¨¦¬®×¡A¥H³æ¿WªvÀø¤§¤è¦¡´ú¸Õ ASLAN003 ¥|ºØ¤£¦P¾¯¶q(100mg QD¡B200mg QD¡B100mg BID¡B200mg BID)¤§Àø®Ä¡C©PÃä¦å²GªÞ²ÓM¼Æ ¥Ø¤j´T°§C¹F 98%¡A¨Ã¦b¼Æ¦ì¯f±w¤¤Æ[¹î¨ìªÞ²ÓM¦bµu®É¶¡¤º¤U°¡AASLAN003 ©ó«æ©Ê°©Åè©Ê¥Õ¦å¯f ¯f±w¦³¨}¦n@¨ü©Ê¡A24 ¦ì¨ü¸ÕªÌ¤¤¥u¦³¤@¦ì¥X²{³QÂkÃþ¬°¸ÕÅçÃÄ«~¬ÛÃöÄY«¤£¨}¨Æ¥ó¤§¶Ý¤¤©Ê¥Õ¦å²y §C¤Uµo¿N»P¸~½F·»¸Ñ¯gÔ¸s¡C¨È·à±d-KY ¥Ø«e¥¿¦b°w¹ï ASLAN003 ¤U¤@¶¥¬q¬ãµo¤è¦V¶i¦æµû¦ô¡C
ASLAN004 • §¹¦¨ ASLAN004 ©ó°·±d¨ü¸ÕªÌ¤§³æ¤@¾¯¶q»¼¼W¸ÕÅç(SAD)¡A¨Ã¤½¥¬¸Ó¸ÕÅç²Ä¤G³¡¤À ASALN004 ¥H¥Ö¤Uª` ®g¤§µ¹ÃĤ覡¤§Á{§É¼Æ¾Ú¡C³æ¤@¾¯¶q»¼¼W¸ÕÅ礧µ²ªGÅã¥Ü ASLAN004 @¨ü©Ê¨}¦n¡A¥i§¹¥þ§í¨î¤U´å¤¶ ½è¡A¥ÎÃÄÀW²v¥i±æ¬°¨C¤ë¤@¦¸¡C • »P CSL Limited ×q±ÂÅv¨óij¡A¨ú±o ASLAN004 ©Ò¦³¾AÀ³¯g¤§¥þ²y¶}µo¡B»s³y»P°Ó«~¤ÆÅv§Q¡C³o¶µ×q ¨óij±N¨ú¥NÂù¤è¥ý«e©ó 2014 ¦~¤¤ë©Òñq¤§¦X¬ù¡C®Ú¾Ú×q¨óij±ø´Ú¡A¨È·à±d-KY ±N©ó ASLAN004 ¤T ´Á¸ÕÅç±Ò°Ê®É¦V CSL º¦¸¤ä¥I 3,000 ¸U¬üª÷¡CCSL ±N¥i¦¬¨ú³Ì°ª¹F 9,500 ¸U¬üª÷¤§ªk³W¥Ó½Ð¶i«×¨½µ{ ª÷¡A³Ì°ª¹F 6.55 »õ¬üª÷¤§¾P°â¨½µ{ª÷¥H¤Î¨Ì¾P°â²bÃB¤À¼h¦¬¨úÓ¦ì¼Æ¤¤¦ì¼Æ¦Ü 10%¤§Åv§Qª÷¡C ¤½¥qÀç¹Bªv²z§ó·s • ¥»¤½¥q¿ï¥ô Andrew Howden ¬°¸³¨Æªø¡C¦Û¤½¥q 2010 ¦~³Ð¥ß¥H¨Ó¾á¥ô¸³¨Æªøº[°õ¦æªøªº Carl Firth ³Õ¤h ±N«ùÄò¾á¥ô¥»¤½¥q°õ¦æªø¤Î¸³¨Æ·|¦¨û¡C¥»¤½¥q¸³¨Æªø©M°õ¦æªøªºÂ¾°È±N¥Ñ¤£¦P¤H¿ï¤À¦Ó¥ô¤§¥H¸¨¹ê ¨}¦nªº¤½¥qªv²z¨î«×¡C
¹wp¹F¦¨¤§¨½µ{¸O • ©ó¤E¤ë©³©ó¼Ú¬w¸~½FÂå¾Ç·|(ESMO) 2019 ¦~¦~·|µoªí varlitinib ¦X¨Ö mFOLFIRI ©ó±ß´Á¹êÅé½F¤§¤@´ÁÁ{§É ¸ÕÅç·s¼Æ¾Ú¡C • ©ó 2019 ¦~¤U¥b¦~®i¶} ASLAN004 ©ó¤¤««×²§¦ì©Ê¥Ö½§ª¢±wªÌ¤§¦h¾¯¶q»¼¼W¸ÕÅç¡C • ©ó 2019 ¦~²Ä¥|©u¨ú±o varlitinib ¤G½uÁx¹DÀù¥þ²y©Ê¼Ï¯Ã¸ÕÅç(TREETOPP)ªì¨BÁ{§É¸ÕÅç¼Æ¾Ú¡C¡@
2019 ¦~²Ä¤G©u°]°È«GÂI • 2019 ¦~²Ä¤G©u¡AÀç¹B¬¡°Ê©Ò¥Î²{ª÷¬° 650 ¸U¬ü¤¸¡A2018 ¦~¦P´Á¬° 1,000 ¸U¬ü¤¸¡C • 2019 ¦~²Ä¤G©u¬ãµo¶O¥Î¬° 530 ¸U¬ü¤¸¡AºÞ²z¶O¥Î¬° 190 ¸U¬ü¤¸¡A2018 ¦~¦P´Á¤À§O¬° 830 ¸U¬ü¤¸»P 310 ¸U¬ü¤¸¡C¬ãµo¶O¥Î¤U°¤§ì¦]¬°³¡¤ÀÁ{§É¸ÕÅ秹¦¨¥H¤Î»s³y¶O¥Î°§C¡CºÞ²z¶O¥Î¤U°¤§ì¦]«h¬° ¤½¥q©ó 2019 ¦~ 1 ¤ë¶i¦æ¤º³¡¬[ºc«¾ã¡C • 2019 ¦~²Ä¤G©u²b·l¬° 790 ¸U¬ü¤¸¡A2018 ¦~¦P´Á²b·l¬° 1,100 ¸U¬ü¤¸¡C • ºI¦Ü 2019 ¦~ 6 ¤ë 30 ¤é¡A²{ª÷¡B¬ù·í²{ª÷©Mµu´Á§ë¸êÁ`ÃB¬° 1,510 ¸U¬ü¤¸ ¡A¥h¦~ºI¦Ü 2018 ¦~ 12 ¤ë 31 ¤é¬° 2,890 ¸U¬ü¤¸¡C2019 ¦~²Ä¤G©u¥[Åv¥§¡流³q¦b¥~ªÑ¼Æ¬° 1.6 »õªÑ¡A2018 ¦~¦P´Á¬° 1.48 »õªÑ¡C ¨C³æ¦ì¬ü°ê¦s°U¾ÌÃÒªí¹ü¨È·à±d-KY ´¶³qªÑ 5 ªÑ
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/8/13 ¤U¤È 05:26:13
²Ä 1190 ½g¦^À³
|
[..as well as results from our ASLAN004 single ascending dose study supporting differentiation versus other IL4/IL13 receptor inhibitors. Based on this exciting new data, we amended the agreement with CSL Limited to include full global rights to develop, manufacture, and commercialise this first in class therapeutic antibody for atopic dermatitis and other indications. ]
®ÇÆ[¤w¤[,·Pı¥H¤W®×±¡¤£³æ¯Â,»ù¦ì±q64©¹¤Uªø¹F16Ó¤ë,À³¸Ó¬O°µ¹Ú³£·|¯º¿ôªº¾÷·|°ª¤@¨Ç! ¦~©³«e³°Äò¤½¥¬¤@¨ÇÁ{§Éµ²ªG,¤pÀ£¤â®ðÅo! |
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/8/13 ¤U¤È 04:15:46
²Ä 1189 ½g¦^À³
|
finance.yahoo.com/news/aslan-pharmaceuticals-reports-second-quarter-080320228.html
ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
we await topline data from our pivotal TreeTopp trial as second line treatment for biliary tract cancer, in the fourth quarter.¡¨
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/13 ¤U¤È 02:51:35
²Ä 1188 ½g¦^À³
|
°]³ø--¶O¥Î¦³¤j´T¤U° ¦ý ²bÈ ¥u³Ñ3.56 ³oÓ°ÝÃD«Ü¤j §C»ù ¦pªGn¶Ò¸ê ªÑ¥»±N¤j¤j¤j¿±µÈ °£«D ¦nªº±ÂÅv Á`Âk ¥[ªo
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GÀ³µL©Ò¦í10144738 |
µoªí®É¶¡:2019/8/13 ¤W¤È 11:21:41
²Ä 1187 ½g¦^À³
|
¦n´Î´Îªº²£«~
¥[ªo
¯¬ºÖ©Ò¦³ªÑªF
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¤Ñ©R10141925 |
µoªí®É¶¡:2019/8/13 ¤W¤È 11:09:11
²Ä 1186 ½g¦^À³
|
ºC©Êªý¶ë©ÊªÍ¯e¯f COPD
Primary Outcome Measures : Annual rate of acute COPD exacerbation (AECOPD) [ Time Frame: Baseline to Week 52 ] Annualized rate of moderate or severe COPD exacerbations over the 52-week treatment period compared to placebo
clinicaltrials.gov/ct2/show/NCT03930732?term=Dupilumab&draw=2&rank=23
Experimental: Dupilumab Dupilumab administered every 2 weeks
COPD (Chronic Obstructive Pulmonary Disease )±wªÌ¶·ªvÀø¤@¦~¡A¬O¤@¦ì²§¦ì©Ê¥Ö½§ª¢ªvÀø4Ӥ몺3¿¥Î¶q¡C
COPD ¥«³õ¨S¦³¯«ÃÄ! ¾Ú¦ôp¡A¸Ó¯f¼vÅT¥þ²y¬ù3.84»õ¤H¡A¹wp¨ì2020±N¦¨¬°²Ä¤T¤jP¦º¦]¯À¡Cªì¦¸¶EÂ_®É¡A¬ù1/3¬°ÄY«©Î«D±`ÄY«ªºCOPDÃþ«¬¡C¥t¥~¡A¬ù¦³30-40%ªº¤¤«×¦Ü««×COPD±wªÌ§Y«K±µ¨ü¤TÁp§l¤JÀøªk¡]ICS/LAMA/LABA¡^¯f±¡¤´¤£¨ü±±¨î¨ÃÄ~Äò´c¤Æ¡C
In 2015, 3.2 million people died from COPD worldwide, an increase of 11.6 percent compared with 1990. During that same time period,
the prevalence of COPD increased by 44.2 percent to 174.5 million individuals. In the United States, an estimated 16 million adults have COPD.2018¦~9¤ë21¤é
¬ü°ê1600¸U¤H±wCOPD , 30%¤¤¡Ð««×, ¥«³õ480¸U¤H , ¬ü°ê700¸U¤H¡A±w²§¦ì©Ê¥Ö½§ª¢.
ªì²¤¦ô¤¤««× COPD¤H¼Æ ¡A¬O¤¤««×²§¦ì¥Ö½§ª¢¤H¼Æ,2.4¿(1700/700=2.4)
Dupilumab ¥«³õ¦ô¬ü°ê¤¤««×¥i½æ¥X50»õ¬ü¤¸(2024¦~), ¦ô COPD ¬ü°ê¥«³õ= 50»õ¬ü¤¸x2.4X3=360»õ¬ü¤¸¡C(¤T´ÁÁ{§É¤¤)
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡G¥xÁÞ10138776 |
µoªí®É¶¡:2019/8/13 ¤W¤È 10:35:05
²Ä 1185 ½g¦^À³
|
¤j®a«Ü¥Î¥\¨Ã«Ü¼ö¯Pªº°Q½× ASLAN 004 À³¥Î¦bCOPD ¯f±w¤W, ³o¬O¤@ӫܦ³¼ç¤Oªº¾AÀ³¯g
¤E¦~«eªº¬ã¨s Interleukin-13: prospects for new treatments
www.ncbi.nlm.nih.gov/pmc/articles/PMC3992377/
¤å³¹«Üªø ¨S®É¶¡¥i¬Ý³Ì«á --- ¥¼¨Óªº¼vÅT
¥¼¨Óªº¼vÅT §Ú̲{¦b¥¿¶i¤J®ð¹D¯e¯fªº·sªvÀø¦~¥N¡C¦b±µ¤U¨Óªº2 - 3¦~¤¤¡AÁ{§É¸ÕÅ窺µ²ªG±N½T©w§ÜIL-13µ¦²¤ªº§@¥Î¡C»P¦¹¦P®É¡A¨ä¥L·sÀøªkªº©w¦ì¡A¥]¬A°w¹ï¨ä¥L²ÓM¦]¤l¡AÁͤƦ]¤l¨üÅé¡A§K¬Ì½Õ¸`¾¯[90]©M¼ö¦¨§Î³N[91]ªº©w¦ì±N¬°§ÚÌ´£¨Ñ¿ï¾Ü¡A¯S§O¬O¦b±w¦³ÄY«ý³Ýªº±wªÌ¤¤¡C³o¨ÇªvÀø¤èªk¤£¤Ó¥i¯à¾A¦X©Ò¦³±wªÌ¡A¦]¦¹±Ný³Ý©MCOPDÃѧO¬°²§½è©Ê¯e¯f±NÅܱo¶V¨Ó¶V«n[92]¡C¥Ø«eÀ³¥Î¨Ã¶}µo·sªºµ²ªG´ú¶q©M¥Íª«¼Ð°Oª«¥H½T«O¬°±wªÌ¿ï¾Ü³Ì¦X¾AªºªvÀø©ÎªvÀø²Õ¦X¡C
§t¦³IL-13§@¬°ý³Ýµo¯f¾÷¨î¤¤ÃöÁä²ÓM¦]¤lªº¤j¶q¼Æ¾Ú´£¨Ñ¤F¤@Ó¥O¤H«HªAªº®×¨Ò¡A¥i¥H¹w´úÁ{§É¤W§ÜIL-13ªº¥i¯à¦¨¥\¡C¦b¤£¤[ªº±N¨Ó¡A§ÚÌn¤£¬O°÷¬°ý³Ý±wªÌ¨Ï¥Î·sÀøªk¡A´N¬O§ÚÌ»Ýn×¥¿ý³Ýªº°ò¥»²z½×
¥H¤W¤À¨É ¶È¨Ñ°Ñ¦Ò
|
|
¡@ |
¦^À³¥»¸ÜÃD
¦^°Q½×°Ï1¶ |
·|û¡GROGER588910148151 |
µoªí®É¶¡:2019/8/13 ¤W¤È 09:43:58
²Ä 1184 ½g¦^À³
|
°²YDupilumab¦bCOPD¤]Àò§å,¨º»ò°ª®p¾P°âÃB>100»õ¬ü¤¸¥i¤£¬O¹Ú.
赛诺µá/¦A¥Í¤¸Dupixentý³ÝÓì应¯g¦A获§å 2024¦~销°â将达80亿med.sina.com/article_detail_100_2_54516.html 该药¦b2024¦~将¦¨为继¦ã§B维׬ü乐¡]Humira¡^¤§¦Zªº¥þ²y²Ä¤G¤j畅销§Üª¢药¡A销°â额将达¨ì80.58亿¬ü¤¸¡A2018-2024¦~ªºÎ`¦X¦~¼W长²v¡]CAGR¡^°ª达64%¡F¨ä¤¤¬ü国¥«场2024¦~销°â额将达¨ì53.7亿¬ü¤¸¡A |
|
¡@ |
¦^°Q½×°Ï1¶ |
<< 5401 ~ 5500 «h¦^ÂÐ >> |